¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2023/2/28 ¤U¤È 09:53:49
²Ä 5983 ½g¦^À³
|
¨rÀYªº¤H¦³±Ï¤F ¤j®a¬èë¨È®v±d |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2023/2/28 ¤U¤È 09:52:23
²Ä 5982 ½g¦^À³
|
ASLAN Pharmaceuticals to Advance Novel DHODH Inhibitor Farudodstat Into Phase 2 Clinical Testing as Potential First-In-Class Treatment for Alopecia Areata ASLAN¨î药¤½¥q将±À进·s«¬DHODH§í¨î剂Farudodstat进¤J2´Á临§É测试¡A§@为ªv疗脱发¯gªºýͦb²Ä¤@类药ª« |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/2/28 ¤U¤È 08:11:57
²Ä 5981 ½g¦^À³
|
aslan003 ³Ì·s¶i«× 2023-02-28 ¡Ä ASLAN Pharmaceuticals ±N·s«¬ DHODH §í»s¾¯ Farudodstat ±À¶i 2 ´ÁÁ{§É¸ÕÅç¡A§@¬°´³¨rªº¼ç¦b¤@¬yªvÀøÃĪ« ´³¨r (AA) ¬O¤@ºØ±`¨£ªº¦Û¨§K¬Ì©Ê¯e¯f¡A¦b¬ü°ê¼vÅT¶W¹L 700,000 ¦W±wªÌ¡A¨ä¯f¦]¬O¤òÅn¤¤§K¬Ì¯SÅv (IP) ªº³à¥¢¥H¤ÎÀH«á¤Àªc IFN£^ ªº§K¬Ì²ÓMªº§ðÀ» Farudodstat ¬O¤@ºØ¦³®Äªº¤fªA DHODH §í»s¾¯¡A¤w³QÃÒ©ú¥i§í¨î IFN£^ ¤Àªc¡A´î¤Ö§K¬Ì²ÓM¼W´Þ¡A¨Ã¥i¯à¦b¤HÃþ AA ¯e¯f¼Ò«¬¤¤¨¾¤î IP ±Y¼ì AA ¤¤ farudodstat ªº 2 ´Á·§©ÀÅçÃÒ¸ÕÅç¹wp±N©ó 2023 ¦~²Ä¤G©u«×¦b¬ü°ê¶}©l©Û¶Ò±wªÌ ASLAN ±N©ó¬ü°êªF³¡®É¶¡ 2023 ¦~ 3 ¤ë 16 ¤é¤W¤È 10:00 ¡V 11:30 »PC¾|¤j¾Ç¥Ö½§¯f¾Ç°Æ±Ð±Â Brett King MD ³Õ¤h¤@°_Á|¿ìÃö©ó farudodstat ªºµêÀÀ¬ãµo¤é¡A°Q½×¾÷ºÞ§½¥¼º¡¨¬ªºÂåÀø»Ý¨D©M·í«eªºªvÀø±¡ªp ¥[§QºÖ¥§¨È¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2023 ¦~ 2 ¤ë 28 ¤é¡]Àô²y·s»DªÀ¡^¡X¡X ASLAN Pharmaceuticals¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¡A¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡A¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬ ¥¦¥¿¦b±À¶i¨äÁ{§Ép¹º¡A¥H¬ã¨s¤fªA¤G²B¨Å²M»Ä²æ²B酶 (DHODH) §í»s¾¯ farudodstat¡A§@¬°´³¨r (AA) ªº¼ç¦b¤@¬yªvÀø¤èªkªº²Ä 2 ¶¥¬q·§©ÀÅçÃÒ¸ÕÅç¡C
AA ¬O¤@ºØ¦Û¨§K¬Ì©Ê¯e¯f¡A¨ä¯S¼x¬O¤òÅn¤¤§K¬Ì¯SÅv (IP) ªº³à¥¢¡A³q¹L I Ãþ¥Dn²Õ´¬Û®e©Ê½Æ¦Xª« (MHC I) ªí¹Fªº¼W¥[¨Ó¿Å¶q¡A¨Ã¥B¬O¥Ñ¤zÂZ¯À£^ (IFN£^) ªº¿E¬¡©M¼W´ÞÅX°Êªº -¤Àªc§K¬Ì²ÓM¤¶¾É¤òÅnªº§ðÀ»¡A¾ÉPÀY¥Ö©M¨Å駹¥þ©Î³¡¤À²æ¾v¡C AA »PÄY«ªº¤ß²zt¾á¬ÛÃö¡AªvÀø¿ï¾Ü¦³¡A¼vÅT¬ü°ê¶W¹L 700,000 ¦W±wªÌ¡C
§í¨î DHODH ¬OªvÀø¦hºØ¦Û¨§K¬Ì©Ê¯e¯fªº¬J©w¾÷¨î¡C DHODH §í»s¾¯¤wÀò§åã¨Ã¼sªx¥Î©ó¦hµo©Êµw¤Æ¯g©MÃþ·Àã©ÊÃö¸`ª¢¡A¦ý²Ä¤@¥N§í»s¾¯ªº®Ä¤O©M¦w¥þ©Ê¯Ê³´¦³¡C Farudodstat ¬O¤@ºØ°ª¿ï¾Ü©Ê DHODH §í»s¾¯¡A¨ä®Ä¤O¬O¦PÃþ¤wÀò§åãÃĪ«ªº 30 ¿¡A¨Ã¥B¨ã¦³¨}¦nªº@¨ü©Ê¦w¥þ©Ê¡C Åé¥~¬ã¨sªí©ú¡Afarudodstat ¥i§í¨î§K¬Ì²ÓM¼W´Þ©M IFN£^ ªº²£¥Í¡C ³Ìªñ¦bÂ÷Åé¤HÃþ AA ¯e¯f¼Ò«¬¤¤ªºÂà¤Æ¬ã¨sªí©ú¡Afarudodstat ´î¤Ö¤F MHC I ³J¥Õ»¤¾É¡A³o¬O IP ·l¥¢ªº¼Ð»x©Ê¯S¼x¡C ¸Ó¼Ò«¬ÁÙ²£¥Í¤F¨ä¥L¥\®Ä¸ñ¶H¡Aªí©ú farudodstat ¥i¯à¼ç¦b¦a«OÅ@¤òÅn§K¨ü¿E¬¡ªº§K¬Ì²ÓMªº§ðÀ»¡C
ASLAN Pharmaceuticals º®u°õ¦æ©x Carl Firth ³Õ¤hµû½×¹D¡G¡§§ÚÌ«Ü°ª¿³±À¶i farudodstat ªºÁ{§É¶}µo¡A¥¦¦³¥i¯à¦¨¬°¤@¬yªºªvÀø¤èªk¡A¸Ñ¨M´³¨r±wªÌ¥¼º¡¨¬ªº»Ý¨D¡C¡¨ ¡§¾¨ºÞ³Ìªñ¦bªvÀø¤è®×¤è±¨ú±o¤F¶i®i¡A¦ý AA Àøªkªºªø´Á¦w¥þ©Ê¤´µM¬OÂå¥Íªººn¥ô°È¡C §Ṳ́w¸g²£¥Í¤F¥O¤H¹ª»Rªº¼Æ¾Ú¡A¤ä«ù§Ú̪º«H©À¡A§Y farudodstat ¥i¥H¹w¨¾¨Ã¥i¯à«ì´_¤òÅn¤¤§K¬Ì¯SÅvªº³à¥¢¡A¬° AA ´£¨Ñ¨ã¦³Ävª§¤Oªº¦w¥þ¦³®ÄªºªvÀø¿ï¾Ü¡C¡¨
2a ´Á·§©ÀÅçÃÒ¸ÕÅç¬O¤@¶µ 2:1 ÀH¾÷¸ÕÅç¡A±wªÌ¨C¤Ñ¨â¦¸¤fªA farudodstat ©Î¦w¼¢¾¯¡A«ùÄò 12 ¶g¡AµM«á¬O¥æ¤eªvÀø´Á¡C ¸Ó¸ÕÅç±N¦b¬ü°ê©Û¶Ò¬ù 60 ¦W±wªÌ¡A¹wp±N©ó 2023 ¦~²Ä¤G©u«×¶}©l¤J²Õ¡C²Ä¤@Ó 12 ©PªvÀø´Á«áªº¤¤´Á³»½uŪ¼Æ¹wp±N©ó 2024 ¦~²Ä¤@©u«×¤½§G¡A¨Ã±N¬°«áÄò 2b ´Áªº³]p´£¨Ñ«H®§ ¾¯¶q½d³ò¬ã¨s¡C ¸Ó¸ÕÅ窺¥Dn¥Øªº¬Oµû¦ô farudodstat ¦b±w¦³ÄY«´³¨rªº¦¨¦~¨ü¸ÕªÌ¤¤ªº¦w¥þ©Ê¡B@¨ü©Ê©M¦³®Ä©Ê¡C
farudodstat µêÀÀ¬ãµo¤é
ASLAN ªººÞ²z¹Î¶¤±N©ó¬ü°êªF³¡®É¶¡ 2023 ¦~ 3 ¤ë 16 ¤é¬P´Á¥|¤W¤È 10:00 ¦Ü¤W¤È 11:30 »PC¾|¤j¾Ç¥Ö½§¯f¾Ç°Æ±Ð±Â Brett King MD ³Õ¤h¤@°_¦b farudodstat ¤WÁ|¿ìµêÀÀ¬ãµo¤é¡C ¶i¤@¨Bªº²Ó¸`±N¦b«á±¡C nµù¥U¸Ó¬¡°Ê¡A½Ð³æÀ»¦¹³B¡C ¬¡°Ê«¼½©Mºt¥Ü§÷®Æ±N¦b ASLAN Pharmaceutical ºô¯¸ªº§ë¸êªÌÃö«Y³¡¤À´£¨Ñ¡C
Ãö©ó farudodstat
Farudodstat ¬O¤@ºØ¦³®Äªº¤fªA DHODH §í»s¾¯¡A¥i³q¹LªýÂ_ DNA ½Æ»s©Ò»ÝªºáGÔr±qÀY²£¥Í¨Ó§í¨î§K¬Ì²ÓM¼W´Þ©M IFN£^ ¤Àªc¡C »P²Ä¤@¥N DHODH §í»s¾¯¬Û¤ñ¡Afarudodstat ¤w³QÃÒ©ú¦b§í¨î DHODH ©M¨î T ²ÓM¬¡©Ê¤è±ªº®Ä¤O¤j¬ù°ª¥X 30 ¿¡A¨Ã¥B¨ã¦³¨}¦nªº@¨ü©Ê¦w¥þ©Ê¡C ASLAN ¥Í¦¨ªº¼Æ¾ÚÅã¥Ü farudodstat |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/2/28 ¤U¤È 08:06:49
²Ä 5980 ½g¦^À³
|
2023-02-28
003 ³Ì·s®ø®§
ASLAN Pharmaceuticals ±N·s«¬ DHODH §í»s¾¯ Farudodstat ±À¶i 2 ´ÁÁ{§É¸ÕÅç¡A§@¬°´³¨rªº¼ç¦b¤@¬yªvÀøÃĪ« ´³¨r (AA) ¬O¤@ºØ±`¨£ªº¦Û¨§K¬Ì©Ê¯e¯f¡A¦b¬ü°ê¼vÅT¶W¹L 700,000 ¦W±wªÌ¡A¨ä¯f¦]¬O¤òÅn¤¤§K¬Ì¯SÅv (IP) ªº³à¥¢¥H¤ÎÀH«á¤Àªc IFN£^ ªº§K¬Ì²ÓMªº§ðÀ» Farudodstat ¬O¤@ºØ¦³®Äªº¤fªA DHODH §í»s¾¯¡A¤w³QÃÒ©ú¥i§í¨î IFN£^ ¤Àªc¡A´î¤Ö§K¬Ì²ÓM¼W´Þ¡A¨Ã¥i¯à¦b¤HÃþ AA ¯e¯f¼Ò«¬¤¤¨¾¤î IP ±Y¼ì AA ¤¤ farudodstat ªº 2 ´Á·§©ÀÅçÃÒ¸ÕÅç¹wp±N©ó 2023 ¦~²Ä¤G©u«×¦b¬ü°ê¶}©l©Û¶Ò±wªÌ ASLAN ±N©ó¬ü°êªF³¡®É¶¡ 2023 ¦~ 3 ¤ë 16 ¤é¤W¤È 10:00 ¡V 11:30 »PC¾|¤j¾Ç¥Ö½§¯f¾Ç°Æ±Ð±Â Brett King MD ³Õ¤h¤@°_Á|¿ìÃö©ó farudodstat ªºµêÀÀ¬ãµo¤é¡A°Q½×¾÷ºÞ§½¥¼º¡¨¬ªºÂåÀø»Ý¨D©M·í«eªºªvÀø±¡ªp |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2023/2/28 ¤U¤È 02:17:17
²Ä 5979 ½g¦^À³
|
1/27¤½§i¦¬®×¤¤¤ß¥Ñ65Ó¼W¥[¦Ü83Ó¡K2/24³Ì«á¤@Ó¯f¤H¤J¦C ±q1b¥H«á¡A²Ó¬Ý¤½¥q¾ãÓÁ{§É¹êÅ窺¥¬§½¤Î¬yµ{¡Bµoªíªº½×¤å Åã¥Ü¤½¥q¹ï004¤´¥Rº¡«H¤ß ˼Æ120¤Ñ¡A¼ÆÄCÀY¶}©l¡K
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2023/2/28 ¤W¤È 10:03:39
²Ä 5978 ½g¦^À³
|
¨S¬Ýì¤å¡Aª½±µ½Æ»s½Ķ ì¨Ó¬O½Õ°¡AÃø©Ç¶^5%¦h ¤£¹LÓ¤H¬Ýªk¡ã°_¥ñÃø§K¡A¥Ø«eÁͶե¼ÅÜ¡I Ä~Äò¬ÝÀ¸
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/28 ¤W¤È 09:43:03
²Ä 5977 ½g¦^À³
|
ASLAN Pharmaceuticals¡¦s PT cut by Piper Sandler to $3.00.
¥t¥~¤@®a¨é°Ó¥ç½Õ°¥Ø¼Ð»ù¥Ñ4¬ü¤¸¦Ü3¬ü¤¸¡D
www.marketbeat.com/stocks/NASDAQ/ASLN/price-target/
ªÑ¥»§Ö³t¼êµÈµ²ªG¡D
2bÀø®Ä¡B¥«³õ预测¥i¯à±µªñLebrikizumab IGA0,1=45% vs15%(¹ï·Ó²Õ)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/28 ¤W¤È 09:17:27
²Ä 5976 ½g¦^À³
|
¨é°Ó¥Ø¼Ð»ù³Ì°ª4.5¬ü¤¸¡D
4.5¬ü¤¸x80%x20¸U¤dªÑADR=7.2»õ¬ü¤¸¥«È 2b 7¤ë¸Ñª¼«á¡B¥«³õ¥]¾P»ù
4.5¬ü¤¸x80%=3.6¬ü¤¸
3.6¬ü¤¸x6¸U¤dªÑADR¬ù2.1»õ¬ü¤¸
¥»¤ë¨p¶Ò2¤d¸U¬ü¤¸+¥¼¨Ó8¤d¸U¬ü¤¸=1»õ¬ü¤¸
¦Xp¶Ò¸ê¬ù3»õ¬ü¤¸¡D
2b¸Ñª¼´Á±æÈ¡G IGA0,1 >44%vs15%(¹ï·Ó组)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/2/27 ¤U¤È 10:34:06
²Ä 5975 ½g¦^À³
|
Hc Wainwright ±N¨È·à±d¥Ø¼Ð»ù½Õ°
¥Ñ7¬ü¤¸ÅÜ4.5¬ü¤¸ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2023/2/27 ¤U¤È 10:09:06
²Ä 5974 ½g¦^À³
|
HC ·Å¿à¯S½Õ¾ãªü´µÄõÃÄ«~ªº¥Ø¼Ð»ù®æ±q $4.50 ±q 7 ¬ü¤¸¡A«O«ù¶R¤Jµû¯Å
¡ã³o®a²´·ú«G¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2023/2/27 ¤U¤È 09:33:38
²Ä 5973 ½g¦^À³
|
ªü·à±q§Ä§Ä¥i¦MÅܦ¨¤¤©Ê¡A¦Ó¬O§_¯àÂର¤@¸ôªø¦h? ´N¨ú¨M©óBVF¬O§_¬Ý¨ìÁͶվÀÂS¤À©úªº¥¿¦Vª¼¼Æ¾Ú¤F¡A¥[ªo~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GPica10150664 |
µoªí®É¶¡:2023/2/27 ¤U¤È 05:12:26
²Ä 5972 ½g¦^À³
|
¨SÂà adr ªº¡C µ¥°t®§¡Aµ¥³Q¨Ö¡Aµ¥Âà adr ¡C²{¦b¤°»ò³£¤£¯à°µ¡A¥u¯àµ¥³o¤TºØ¾÷·|¨ÓÁ{¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2023/2/27 ¤U¤È 02:29:33
²Ä 5971 ½g¦^À³
|
³oÃ䦳¨È®v±d¿à¸s¶Ü? ÁÙ¦³§Ú¬O¤§«e¥xªÑ¶Rªº ¦¨¥»¤ñ²{¦b°ª«Ü¦h ±i¼Æ¤£¦h §Ñ¤F¸òµÛÂà´«ADR ¥Ø«eÁö¬OªÑªF ¦ý¬O¨S¦³±b¤áªÑ¼Æ¥i¥H¥æ©ö ³on«ç»ò³B²z?
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2023/2/26 ¤U¤È 07:04:23
²Ä 5970 ½g¦^À³
|
²ö°Ý¦h¤Ö¡A¥ý°Ý¦Û¤v¦³¦h¤Ö¡H¦@«j¡I¨þ¨þ😄 µ¹§AÓ¤]³\·|¦¨¯uªº¹Ú¡ã
¡§·í±z«ù¦³ASLN 25,000ªÑADR, 2-3¦~¤º¤½¥q³Q¨ÖÁÊ,¥Ø¼Ð¨ÖÁÊ»ù60¬ü¤¸/ADR ¸ê²£¦³¾÷·|¤W¬Ý150¸U¬ü¤¸.¦¨¬°¥xÆW«e1%´I¯Î.¡¨
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2023/2/26 ¤U¤È 03:08:15
²Ä 5969 ½g¦^À³
|
½Ð°Ý¤j®a ¬OADR¤~¶RªºÁÙ¬O¦b¥x±¾µP®É¤w¸g¶Rªº ¦¨¥»¦h¤Ö°Ú? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2023/2/25 ¤W¤È 01:32:37
²Ä 5968 ½g¦^À³
|
¤½¥q¥ø¹Ï¤ß«Ü±j¡A°]°Èª¬ªpÀò±o§O®a¤½¥q¬Û®¼»P§ïµ½¨Ï¬I®i·~°ÈªºªÅ¶¡§ó¥[¶}ÂX¡A·Ó³oºØº¦´T¤ë©³´N·|¹L1¬ü¤¸¡A¤T¤ë¹L3¬ü¤¸¡A¨ì¤C¤ë¤½§G´Á¤¤¼Æ¾Úè¦n¹L7¬ü¤¸²Å¦X§ë¸ê¾÷ºc¹w´Á¡Aµ¥«Ý¨H¨S¤w¤[ªº¨È´µÄõ}´µ¸¹°_¸¼Q¥X¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2023/2/24 ¤U¤È 10:46:35
²Ä 5967 ½g¦^À³
|
1¤¸«O½Ã¾Ô¡A´N¥æµ¹BVF Partners LP¤F.... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/24 ¤U¤È 10:17:19
²Ä 5966 ½g¦^À³
|
³o¼Ëªº»{ªÑÅv§G§½¡AÓ¤H§PÂ_¡G¥Dn½T«O¯à¦b¶i¤J¤T´Á®É¡A¯à¤ä¥I3000¸U¬ü¤¸µ¹CSL¡A¦Ó¶¶§Q®i¶}¡C
¶i®i¨ì2024¦~Q2¡A§Æ±æ¦b¦¹¤§«e¯à³Q¨ÖÁʱ¼¡C
2b ¸Ñª¼¼Æ¾Ú¯à¶W¶V¹w´Á IGA0,1 >44%vs 15%(¹ï·Ó²Õ¡^
¥H¤W¼Æ¾Ú¨é°Óµ¹4¡ã7¬ü¤¸ªº¥Ø¼Ð»ù¡C
4x50%=2¬ü¤¸ 7x50%=3.5¬ü¤¸
¥»¦¸ 1.3¡ã2¡ã3¡P5¬ü¤¸ªº»{ªÑÅvÃÒÃÒ»ù´Á±æÈ¡C
¦pªGIGA0,1 ¯à©¹¤W©Ô¨ì50%¡ã60%¥«³õ¤~·|©Ô°ª¥Ø¼Ð»ù¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2023/2/24 ¤U¤È 10:02:50
²Ä 5965 ½g¦^À³
|
°Ó·~½Í§P¬O²{¹êªº¡A ¨S¦³¼ç¦b§Q¯q¡A½ÖÄ@·N±Ç¿ú¡H ¨S¦³°Â°â¡AÅSÓ»ùÈ¡A½Öª¾¹D¦³¼ç¦b§Q¯q¡H
³ÌºC3/16¤§«e¡A1¤¸±N¦¨¾ú¥v |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/24 ¤U¤È 09:46:02
²Ä 5964 ½g¦^À³
|
As part of the financing, the Investors will also receive two tranches of warrants initially exercisable in the aggregate for up to 55,309,112 ADSs (or pre-funded warrants).
The first tranche of warrants is comprised (i) 50% of purchase warrants that are exercisable upon issuance and until sixty days after the public announcement of ASLAN¡¦s topline data from its TREK-AD Phase 2b clinical trial investigating eblasakimab in atopic dermatitis at an exercise price of $1.30 per ADS and ¤@¤@¤@¤@ (ii) 50% of purchase warrants which can only be exercised within sixty days after the public announcement of ASLAN¡¦s topline data from its TREK-AD Phase 2b clinical trial investigating eblasakimab in atopic dermatitis at an exercise price based on the higher of $1.30 and a 50% discount to the ADS VWAP measured across a specified period after the public announcement of data.
ii) 50%ªº购买权证¡A¥u¯à¦bASLAN¤½开«Å¥¬¨ä调¬d¥ì¥¬©Ô¦è单§Üªv疗¯S应©Ê¥Öª¢ªºTREK-AD 2b´Á临§É试验ªº顶线数Õu¦Z60¤Ñ内¦æ¨Ï¡A¦æ¨Ïɲ°ò¤_1.30¬ü¤¸©M¤½开«Å¥¬数Õu¦Z¯S©w时´Á内¬ü国¦s¦«ú«证VWAP¡]¯S©w´Á¶¡ADR¥§¡»ù®æ¡^ªº50%§é¦©¡A¥H两ªÌ¤¤较°ªªÌ为ã¡C
xxxVWAP¡G¦p¤½¥¬¸Ñª¼¼Æ¾Ú«áADR 10¤Ñªº¥§¡»ù®æ x50% Y¤Wº¦¦Ü¥§¡7¬ü¤¸¡A«h7x50%=3.5¬ü¤¸¨CªÑADR°µ¬°»{ÁÊ»ù¡A«D1.3¬ü¤¸¡C ¤@¤@¤@¤@ The second tranche of warrants is similarly comprised (i) 50% of purchase warrants that are exercisable upon issuance until sixty days after the public announcement of topline interim data from ASLAN¡¦s planned Phase 2 proof of concept trial investigating farudodstat at an exercise price of $1.63 per ADS and ( ¤@¤@¤@ ii) 50% of purchase warrants which can only be exercised within sixty days after the public announcement of topline interim data from ASLAN¡¦s planned phase 2 proof of concept trial investigating farudodstat at an exercise price based on the higher of $1.63 and a 50% discount to the ADS VWAP measured across a specified period after the public announcement of data.
ii¡^50%ªº购买权证¡A¥u¯à¦bASLAN计¦Eªº调¬dfarudodstatªº²Ä¤G阶¬q·§©À验证试验ªº顶线¤¤´Á数Õu¤½¥¬¦Z60¤Ñ内¦æ¨Ï¡A¦æ¨Ïɲ为1.63¬ü¤¸©M数Õu¤½¥¬¦Z¯S©w时´Á内¬ü国¦s¦«ú«证VWAPªº50%§é¦©¡A¥H两ªÌ¤¤较°ªªÌ为ã¡C
Both tranches of the purchase warrants also include a mandatory exercise provision subject to the satisfaction of certain pre-specified conditions.
这两§å购买权证还¥]¬A¤@个üL¨î¦æ¨Ï条´Ú¡A¦ý¥²须满¨¬¬Y¨Ç预¥ý«ü©wªº条¥ó¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2023/2/24 ¤U¤È 08:55:31
²Ä 5963 ½g¦^À³
|
¤¤©Ê°¾¦hªº¨p¶Ò¡A¬Ý¨Ó¤£·|´î¸ê¤F¡A·à¤ÍÌ¡A¥[ªo!! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/24 ¤U¤È 08:54:50
²Ä 5962 ½g¦^À³
|
¦p¤µ¤é¤½¥¬¡G¤w¦¬³Ì«á¤@¦ì±wªÌ¡A´Nµ¥7¤ë¤¤¦¯¸Ñª¼³ø§i¡A ¥t¤@½¤j¶Ò¸ê¡A¥t¶Ò3¡ã4»õ¬ü¤¸¡A¤~¨¬¥Hû£°Ê¤T´ÁÁ{§É¡A ¥t¥~¶·±ÂÅv¼Ú¬w°Ï°Ó·~¤ÆÅv§Q¡A¥H¤ä¥ICSL 3000¸U¬ü¤¸ªº¤T´Áû£°Ê¶O¥[9000¸U¬ü¤¸¡]ùµ{ª÷¡A¥i¯à¨ìÃÄÃÒ®Öµo¡^¡C
³o¬Oªº¨p¶Ò¦b凖³Æ©ÔªÑ»ù¥Îªº¡A¥Î±¼2¸U¦hªÑADR¡Cµo¦æ¶qªñ10¸UªÑADR¡Cx1.3¬ü¤¸¡A¥«È¤´¥u¦³1»õ3¤d¸U¬ü¤¸¡C
¤@¤@¬ü°ê°ê¼y°²´Á7¤ë4¤é¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/2/24 ¤U¤È 08:27:30
²Ä 5961 ½g¦^À³
|
µ}ÄÀªÑÅv¤£¥i©È¡A·sÃĪѦ³¿ú(ÁÙ¦³¤Hn)¤ñ¸û«n §A¬Ý¹j¾À´×ªº¬P¤]¬O§C»ù¤j¨p¶Ò¼W¥[¶W¦hªÑ¥»¡A¦ýªÑ»ùº¦¤£´N¦n¤F «ÂIÁÙ¬O¹êÅç¼Æ¾Ú¦n¤£¦n ˬO¤Ñ©R¤jªº5.6¤¸¼W¸ê¦b³o®É¶¡ÂI¥»¨Ó´N¤£¥i¯à ²{¦b³£ÁÙ¨SºÝ¥X¦n¼Æ¾Ú¡A½Ö·|¸ò§A·¸»ù8¿¶R
n¬O²{¦b³oµ§¨p¶Ò¯à§âªÑ»ù±À¤W1¬ü¤¸¡A§Ú´Nı±o«Ü¦¨¥\¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/2/24 ¤U¤È 08:26:33
²Ä 5960 ½g¦^À³
|
§Úı±o«ÂI¦³2
¤@. 004 2b©Û¶Ò¯f¨Ò¤Hû¤w§¹¦¨¡A²{¥uµ¥«áÄòÃĮĦ¨ªG¡A¤µ¦~7¤ëªì§Y¥i¸Ñª¼¡A ¦¨±Ñ´N¦b¦¹Á|¡A
¤G.¥Ø«e¨È·à±dÀ³´¤¦³¤@¨Ç´Á¤¤¼Æ¾Ú¡A¥B¼Æ¾Ú¥¿¦V¡A¤~·|¦³¤½¥qÄ@·N¦¹®É°Ñ¥[¨p¶Ò¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/2/24 ¤U¤È 08:18:32
²Ä 5959 ½g¦^À³
|
³o¤£ºâ³Î´µæ§a «ç»ò¬Ý³£ºâ§Q¦h¡AÁٯ෸»ù¨p¶Ò«Ü¦n¤F(ÁÙ¦³¤Hn) ¤@°ï¨p¶Ò³£¬O¤j¬å»ù½â»ù¶Ò ¤ñÃz±¼¦n¦h¤F...·Pı¦³¾÷·|¤W1¬ü¤¸ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2023/2/24 ¤U¤È 08:18:27
²Ä 5958 ½g¦^À³
|
«Ó°¶¤j¡A·íµM¨S¦³§A̪º¥÷¡A¤§«eªº¼W¸ê³£±ÂÅvµ¹¸³¨Æ·|¥h¿ì²z¤F¡A³oºØ¨p¶Ò·íµM¬O§ä¦n¯S©w¾÷ºc§ë¸êªÌ¥h¿ì²z¨p¶Ò¡A©Ò¥H§Ú¤~»¡¾a³oºØ¨p¶Òµ}ÄÀ§A¦U¦ìªÑÅv¡A´Nºâ³Ì«áaslan004¦³¦nµ²ªG¡A§A¦U¦ì©¾¹êªºªÑªF³ø¹S²v¤]¨S·Q¹³¤¤°ª¡A¦ýn©Ó¾á¥¢±ÑÅܾÀ¯Èªº·ÀI¡A¦Ó¥B³o¦¸¨p¶Ò»ù®æ·¥§C¡A¤Ñ©R¤jºâªº¥Ø¼Ð»ù7*0.8=5.6¼W¸ê»ù¡A¬Ý¨Ó¬O¦³¤@¬q¤£¤pªº¸¨®t©O~~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/2/24 ¤U¤È 08:12:57
²Ä 5957 ½g¦^À³
|
¦³ÂI¤£À´§ë¸êªÌ¨p¶Òªº³¡¤À ·N«ä¬O§Ṳ́]¥i¥H°Ñ¥[¨p¶Ò? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2023/2/24 ¤U¤È 08:09:51
²Ä 5956 ½g¦^À³
|
¨Ó¤F¨Ó¤F¡AÀH«K¤@Ó¼W¸ê¡A³Ì°ª5500¸UªÑADS¡A§A¦U¦ìªºªÑÅv³Qµ}ÄÀ¤F§Ö¤@¥b¡A¦Ó¥B¤~0.89¤@ªÑ¡A«áÄò¿ï¾ÜÅv¥i¥H¥Î1.6¸ò1.63¤¸¶R¤J¡A¯uªº¬O³Q·í´µæ³Î²n²nXD |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/2/24 ¤U¤È 07:17:30
²Ä 5955 ½g¦^À³
|
2023-02-24 ASLAN Pharmaceuticals «Å¥¬¥Ñ BVF Partners LP ²oÀYªº 2000 ¸U¬ü¤¸¨p¶Ò°t°â¡A¨Ã¦³¥i¯àÃB¥~Àò±o°ª¹F 8000 ¸U¬ü¤¸ ASLAN ±NÀò±o 2000 ¸U¬ü¤¸ªº¿Ä¸ê¡A¨Ã¦³¥i¯àÀò±o°ª¹F 8000 ¸U¬ü¤¸ªºÃB¥~¸êª÷¡AÁ`p 1 »õ¬ü¤¸¥Î©óÄ~Äò±À¶ieblasakimab©MfarudodstatªºÁ{§É¶}µo ASLAN ªº¹w´Á²{ª÷¶]¹D¦Ü¤Ö©µªø¨ì 2024 ¦~²Ä¤G©u«×¡A¨Ã¥i¯à®Ú¾Ú 2023 ¦~ 7 ¤ëªì TREK-AD ¬ã¨sªº¥Dn¼Æ¾ÚŪ¥X©Mp¹º©ó 2024 ¦~¶i¦æªº farudodstat ·§©ÀÅçÃÒ¸ÕÅç«á¥i¦æ¨ÏªºÃB¥~»{ªÑÅvÃÒ¶i¤@¨B¦æÅv ¦Û¨§K¬Ì©Ê¥Ö½§¯fªºFarudodstat·§©ÀÅçÃÒ¸ÕÅç¹wp±NÀò±o¥þÃB¸ê§Uª½¦Ü§¹¦¨ ¥[§QºÖ¥§¨È¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2023 ¦~ 2 ¤ë 24 ¤é¡]Àô²y·s»DªÀ¡^-- ASLAN Pharmaceuticals¡]¡§ASLAN¡¨¡A¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¡A¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¤wñq³Ì²×ÁʶR¨óij¡]¡§ÁʶR¨óij¡¨¡^¡A¥HÁʶR»ù®æ¥X°â¨ä´¶³qªÑ¡]©Î¹w¥ý´£¨Ñ¸êª÷ªº»{ªÑÅvÃÒ¡^©MÀHªþªºÁʶR»{ªÑÅvÃÒ¡AÄw¶°¬ù 2000 ¸U¬ü¤¸ªºÁ`¦¬¯qBVF Partners LP¡BK2 HealthVentures ©M¬Y¨Ç²{¦³§ë¸êªÌ¡]¡§§ë¸êªÌ¡¨¡^¨CªÑ´¶³qªÑ 0.178 ¬ü¤¸¡]©Î¬Û·í©ó¨CªÑ¬ü°ê¦s°UªÑ¥÷¡]¡§ADS¡¨¡^0.89 ¬ü¤¸¡^¡C¦¹¥~¡A
¡§§ÚÌ«D±`°ª¿³±o¨ì BVF Partners ©M§Ú̲{¦³§ë¸êªÌªº¤ä«ù¡AÀ°§U±À¶i§Ú̪º¨âÓªvÀø¶µ¥Ø¡A¨Ã¦b¤µ¦~ 7 ¤ëªì§Ú̹ïeblasakimabªº TREK-AD ¬ã¨sªº¹w´ÁŪ¥X³»½u¼Æ¾Ú¤§«e¥[±j§Ú̪º¸ê²£t¶Åªí¦~¡A¡¨ ASLAN Pharmaceuticals º®u°õ¦æ©x Carl Firth³Õ¤h »¡¡C¡§¨Ó¦Û³o¨Çª¾¦W±M·~§ë¸êªÌªº¸êª÷¤ä«ù¬O¹ïeblasakimab§@¬°¯SÀ³©Ê¥Öª¢±wªÌªº·s«¬®t²§¤ÆªvÀøÃĪ«ªº¼ç¤Oªº±j¯P»{¥i¡A¥H¤Îfarudodstat§@¬°¦Û¨§K¬Ì©Ê¥Ö½§¯f DHODH ªº¤U¤@¥N±j®Ä¤fªA§í»s¾¯ªº¼ç¤O¡C¡¨
¥»¦¸¿Ä¸ê²Å¦XºD¨Ò¦¨¥æ±ø¥ó¡A¹wp±N©ó 2023 ¦~ 2 ¤ë 27 ¤é©Î«e«á§¹¦¨¡C®Ú¾ÚÁʶR¨óijªº±ø´Ú¡A¨È·à±d±Nµo¦æ¦Xp 112,359,550 ªÑ´¶³qªÑ¡]©Î¹w¥ýµù¸ê»{ªÑÅvÃÒ¡^¡A¬Û·í©ó¦Ü 22,471,910 ¥÷¬ü°ê¦s°U¾ÌÃÒ¡A¬Û·í©ó¨C¥÷¬ü°ê¦s°U¾ÌÃÒ 0.89 ¬ü¤¸ªº»ù®æ¡A¤ñ¨C¥÷¬ü°ê¦s°U¾ÌÃÒ 0.77 ¬ü¤¸ªº¬ü°ê¦s°U¾ÌÃÒ¤Q¤Ñ¦¨¥æ¶q¥[Åv¥§¡»ù®æ (VWAP) ·¸»ù 15%¡CASLAN ¥´ºâ±N¨p¶Òªº²b¦¬¯q¥Î©óÀç¹B¸êª÷©M¤@¯ë¤½¥q¥Î³~¡A¥]¬Aeblasakimab©MfarudodstatªºÁ{§É¶}µo¡C
§@¬°¿Ä¸êªº¤@³¡¤À¡A§ë¸êªÌÁÙ±N¦¬¨ì¨â§å³Ìªì¥i¦æ¨Ïªº»{ªÑÅvÃÒ¡AÁ`p³Ì¦h 55,309,112 ¥÷¬ü°ê¦s°U¾ÌÃÒ¡]©Î¹w¥ý¿Ä¸êªº»{ªÑÅvÃÒ¡^¡C²Ä¤@§å»{ªÑÅvÃÒ¥]¬A (i) 50% ªº»{ªÑÅvÃÒ¡A¥i¦bµo¦æ«á¦æ¨Ï¡Aª½¦Ü¨È·à±d¥H¦æ¨Ï»ù¤½§G¨ä TREK-AD 2b ´ÁÁ{§É¸ÕÅ窺 TREK-AD 2b ´ÁÁ{§É¸ÕÅ窺¥Dn¼Æ¾Ú«á¤»¤Q¤Ñ¥H¦æ¨Ï»ù¦æ¨Ï¨C ADS 1.30 ¬ü¤¸©M (ii) 50% ªºÁʶRÅvÃÒ¡A¥u¯à¦b ASLAN ±q¨ä TREK-AD 2b ´ÁÁ{§É¸ÕÅ礤½Õ¬d eblasakimab ªvÀø¯SÀ³©Ê¥Öª¢ªº³»½u¼Æ¾Ú¤½§G«á¤»¤Q¤Ñ¤º¦æ¨Ï§ó°ª1.30 ¬ü¤¸©M 50% ªº§é¦©¡A¦b¼Æ¾Ú¤½§G«áªº¯S©w®É´Á¤º´ú±oªº ADS VWAP¡C²Ä¤G§å»{ªÑÅvÃÒ¦P¼Ë¥]§t (i) 50% ªº»{ªÑÅvÃÒ¡A³o¨Ç»{ªÑÅvÃÒ¦bµo¦æ«á¥i¦æ¨Ï¡Aª½¦Ü¨È·à±dp¹ºªº²Ä¤G¶¥¬q·§©ÀÅçÃÒ¸ÕÅç½Õ¬dfarudodstatªº¤¤´Á¼Æ¾Ú¤½§G«á¤»¤Q¤Ñ¡A¦æ¨Ï»ù¬°¨CªÑ 1.63¬ü¤¸ADS ©M (ii) 50% ªºÁʶRÅvÃÒ¥u¯à¦b ASLAN p¹ºªº²Ä¤G¶¥¬q·§©ÀÅçÃÒ¸ÕÅ窺¥Dn¤¤´Á¼Æ¾Ú¤½§G«á¤»¤Q¤Ñ¤º¦æ¨Ï¡A¸Ó¸ÕÅç¥H¸û°ªªº¦æ¨Ï»ù½Õ¬dfarudodstat1.63 ¬ü¤¸¡A¨Ã¥B¦b¼Æ¾Ú¤½§G«áªº¯S©w®É´Á¤º´ú±oªº ADS VWAP ¦³ 50% ªº§é¦©¡C¨â§åÁʶRÅvÃÒÁÙ¥]¬A¦bº¡¨¬¬Y¨Ç¹w¥ý³W©wªº±ø¥óªº±¡ªp¤Uªº±j¨î¦æÅv±ø´Ú¡C
±N¦b¨p¶Ò¤¤¥X°âªºÃÒ¨é¡A¥]¬A»{ªÑÅvÃÒ©M¦æ¨Ï»{ªÑÅvÃÒ«á¥iµo¦æªºÃÒ¨é¡A©|¥¼®Ú¾Ú¸g×qªº 1933 ¦~ÃÒ¨éªk¡]¡§ÃÒ¨éªk¡¨¡^©Î¥ô¦ó¦{©Î¨ä¥L¾A¥ÎªºÃÒ¨éªk¶i¦æµn°O¥qªkºÞÁҰϪºÃÒ¨éªk¡A¨Ã¥B¤£±o¦b¨S¦³µù¥U©Î¥¼¾A¥Î¡mÃÒ¨éªk¡n©M¾A¥Î¦{©Î¨ä¥L¥qªkºÞÁÒ°ÏÃÒ¨éªkªºµù¥Un¨DÁŧKªº±¡ªp¤U¦b¬ü°êµo°â©Î¥X°â¡C¤½¥q¤w¦P·N¦V¬ü°êÃÒ¨é¥æ©ö©eû·|¡]¡§SEC¡¨¡^´£¥æ¤@¥÷µn°OÁn©ú¡Aµn°O¦b¨p¶Ò¤¤µo¦æªºÃҨ骺Âà°â¡C
¥»·s»D½Z¤£ºc¦¨¥X°â³o¨ÇÃҨ骺n¬ù©ÎÁʶR³o¨ÇÃҨ骺n¬ùÁܽСA¤]¤£ºc¦¨¦b¥ô¦ó¥qªkºÞÁҰϤº¹ï³o¨ÇÃҨ骺¥ô¦ón¬ù¡BÁܬù©Î¥X°â¡A¦pªG¦¹Ãþn¬ù¡B©ÛÅó©Î¥X°â¬O«Dªkªº¡C®Ú¾ÚÂà°âµn°OÁn©ú´£¨Ñªº¥ô¦óÃÒ¨é±N¥u¯à³q¹L©ÛªÑ»¡©ú®Ñªº¤è¦¡¶i¦æ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/2/24 ¤U¤È 07:12:13
²Ä 5954 ½g¦^À³
|
2023-02-24 ASLAN Pharmaceuticals «Å¥¬¥Ñ BVF Partners L.P. ²oÀYªº 2000 ¸U¬ü¤¸¨p¶Ò°t°â¡A¨Ã¦³¥i¯àÃB¥~Àò±o°ª¹F 8000 ¸U¬ü¤¸ ASLAN ±NÀò±o 2000 ¸U¬ü¤¸ªº¿Ä¸ê¡A¨Ã¦³¥i¯àÀò±o°ª¹F 8000 ¸U¬ü¤¸ªºÃB¥~¸êª÷¡AÁ`p 1 »õ¬ü¤¸¥Î©óÄ~Äò±À¶i eblasakimab ©M farudodstat ªºÁ{§É¶}µo ASLAN ªº¹w´Á²{ª÷¶]¹D¦Ü¤Ö©µªø¨ì 2024 ¦~²Ä¤G©u«×¡A¨Ã¥i¯à®Ú¾Ú 2023 ¦~ 7 ¤ëªì TREK-AD ¬ã¨sªº¥Dn¼Æ¾ÚŪ¥X©M 2024 ¦~p¹ºªº farudodstat ·§©ÀÅçÃÒ¸ÕÅç«á¥i¦æ¨ÏªºÃB¥~»{ªÑÅvÃÒ¶i¤@¨B¦æÅv ¦Û¨§K¬Ì©Ê¥Ö½§¯fªº Farudodstat ·§©ÀÅçÃÒ¸ÕÅç¹wp±NÀò±o¥þÃB¸ê§Uª½¦Ü§¹¦¨ ¥[§QºÖ¥§¨È¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2023 ¦~ 2 ¤ë 24 ¤é¡]Àô²y·s»DªÀ¡^-- ASLAN Pharmaceuticals¡]¡§ASLAN¡¨¡A¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¡A¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡ ¡A¤µ¤Ñ«Å¥¬¤wñq³Ì²×ÁʶR¨óij¡]¡§ÁʶR¨óij¡¨¡^¡A¥HÁʶR»ù®æ¥X°â¨ä´¶³qªÑ¡]©Î¹w¥ý´£¨Ñ¸êª÷ªº»{ªÑÅvÃÒ¡^©MÀHªþªºÁʶR»{ªÑÅvÃÒ¡AÄw¶°¬ù 2000 ¸U¬ü¤¸ªºÁ`¦¬¯q BVF Partners L.P.¡BK2 HealthVentures ©M¬Y¨Ç²{¦³§ë¸êªÌ¡]¡§§ë¸êªÌ¡¨¡^¨CªÑ´¶³qªÑ 0.178 ¬ü¤¸¡]©Î¬Û·í©ó¨CªÑ¬ü°ê¦s°UªÑ¥÷¡]¡§ADS¡¨¡^0.89 ¬ü¤¸¡^¡C ¦¹¥~¡A¦pªG»PÁʶR¨óij¬ÛÃöªº©Ò¦³ÁʶRÅvÃÒ³£±o¨ì¥R¤À¦æ¨Ï¡AASLAN ±N¦³¥i¯àÀò±o°ª¹F 8000 ¸U¬ü¤¸ªºÃB¥~¦¬¤J¡C
¡§§ÚÌ«D±`°ª¿³±o¨ì BVF Partners ©M§Ú̲{¦³§ë¸êªÌªº¤ä«ù¡AÀ°§U±À¶i§Ú̪º¨âÓªvÀø¶µ¥Ø¡A¨Ã¦b¤µ¦~ 7 ¤ëªì§Ú̹ï eblasakimab ªº TREK-AD ¬ã¨sªº¹w´ÁŪ¥X³»½u¼Æ¾Ú¤§«e¥[±j§Ú̪º¸ê²£t¶Åªí ¦~¡A¡¨ASLAN Pharmaceuticals º®u°õ¦æ©x Carl Firth ³Õ¤h»¡¡C ¡§¨Ó¦Û³o¨Çª¾¦W±M·~§ë¸êªÌªº¸êª÷¤ä«ù¬O¹ï eblasakimab §@¬°¯SÀ³©Ê¥Öª¢±wªÌªº·s«¬®t²§¤ÆªvÀøÃĪ«ªº¼ç¤Oªº±j¯P»{¥i¡A¥H¤Î farudodstat §@¬°¦Û¨§K¬Ì©Ê¥Ö½§¯f DHODH ªº¤U¤@¥N±j®Ä¤fªA§í»s¾¯ªº¼ç¤O¡C¡¨
¥»¦¸¿Ä¸ê²Å¦XºD¨Ò¦¨¥æ±ø¥ó¡A¹wp±N©ó 2023 ¦~ 2 ¤ë 27 ¤é©Î«e«á§¹¦¨¡C®Ú¾ÚÁʶR¨óijªº±ø´Ú¡A¨È·à±d±Nµo¦æ¦Xp 112,359,550 ªÑ´¶³qªÑ¡]©Î¹w¥ýµù¸ê»{ªÑÅvÃÒ¡^¡A¬Û·í©ó ¦Ü 22,471,910 ¥÷¬ü°ê¦s°U¾ÌÃÒ¡A¬Û·í©ó¨C¥÷¬ü°ê¦s°U¾ÌÃÒ 0.89 ¬ü¤¸ªº»ù®æ¡A¤ñ¨C¥÷¬ü°ê¦s°U¾ÌÃÒ 0.77 ¬ü¤¸ªº¬ü°ê¦s°U¾ÌÃÒ¤Q¤Ñ¦¨¥æ¶q¥[Åv¥§¡»ù®æ (VWAP) ·¸»ù 15%¡C ASLAN ¥´ºâ±N¨p¶Òªº²b¦¬¯q¥Î©óÀç¹B¸êª÷©M¤@¯ë¤½¥q¥Î³~¡A¥]¬A eblasakimab ©M farudodstat ªºÁ{§É¶}µo¡C
§@¬°¿Ä¸êªº¤@³¡¤À¡A§ë¸êªÌÁÙ±N¦¬¨ì¨â§å³Ìªì¥i¦æ¨Ïªº»{ªÑÅvÃÒ¡AÁ`p³Ì¦h 55,309,112 ¥÷¬ü°ê¦s°U¾ÌÃÒ¡]©Î¹w¥ý¿Ä¸êªº»{ªÑÅvÃÒ¡^¡C ²Ä¤@§å»{ªÑÅvÃÒ¥]¬A (i) 50% ªº»{ªÑÅvÃÒ¡A¥i¦bµo¦æ«á¦æ¨Ï¡Aª½¦Ü¨È·à±d¥H¦æ¨Ï»ù¤½§G¨ä TREK-AD 2b ´ÁÁ{§É¸ÕÅ窺 TREK-AD 2b ´ÁÁ{§É¸ÕÅ窺¥Dn¼Æ¾Ú«á¤»¤Q¤Ñ¥H¦æ¨Ï»ù¦æ¨Ï ¨C ADS 1.30 ¬ü¤¸©M (ii) 50% ªºÁʶRÅvÃÒ¡A¥u¯à¦b ASLAN ±q¨ä TREK-AD 2b ´ÁÁ{§É¸ÕÅ礤½Õ¬d eblasakimab ªvÀø¯SÀ³©Ê¥Öª¢ªº³»½u¼Æ¾Ú¤½§G«á¤»¤Q¤Ñ¤º¦æ¨Ï ¦b¼Æ¾Ú¤½§G«áªº¯S©w®É´Á¤º´ú±oªº ADS VWAP °ª©ó 1.30 ¬ü¤¸©M 50% ªº§é¦©¡C ²Ä¤G§å»{ªÑÅvÃÒ¦P¼Ë¥]§t (i) 50% ªº»{ªÑÅvÃÒ¡A³o¨Ç»{ªÑÅvÃÒ¦bµo¦æ«á¥i¦æ¨Ï¡Aª½¦Ü¨È·à±dp¹ºªº²Ä¤G¶¥¬q·§©ÀÅçÃÒ¸ÕÅç½Õ¬d farudodstat ªº¤¤´Á¼Æ¾Ú¤½§G«á¤»¤Q¤Ñ¡A¦æ¨Ï»ù¬°¨CªÑ 1.63 ¬ü¤¸ ADS ©M (ii) 50% ªºÁʶRÅvÃÒ¥u¯à¦b ASLAN p¹ºªº²Ä¤G¶¥¬q·§©ÀÅçÃÒ¸ÕÅ窺³»¯Å¤¤´Á¼Æ¾Ú¤½§G«á¤»¤Q¤Ñ¤º¦æ¨Ï¡A¸Ó¸ÕÅç¥H 1.63 ¬ü¤¸©M 50 ¬ü¤¸ªº¸û°ªªÌ¬°°ò¦½Õ¬d farudodstat ¼Æ¾Ú¤½§G«á¯S©w®É´Á¤º´ú±oªº ADS VWAP §éÅý¦Ê¤À¤ñ¡C ¨â§åÁʶRÅvÃÒÁÙ¥]¬A¦bº¡¨¬¬Y¨Ç¹w¥ý³W©wªº±ø¥óªº±¡ªp¤Uªº±j¨î¦æÅv±ø´Ú¡C
±N¦b¨p¶Ò¤¤¥X°âªºÃÒ¨é¡A¥]¬A»{ªÑÅvÃÒ©M¦æ¨Ï»{ªÑÅvÃÒ«á¥iµo¦æªºÃÒ¨é¡A©|¥¼®Ú¾Ú¸g×qªº 1933 ¦~ÃÒ¨éªk¡]¡§ÃÒ¨éªk¡¨¡^©Î¥ô¦ó¦{©Î¨ä¥L¾A¥ÎªºÃÒ¨éªk¶i¦æµn°O ¥qªkºÞÁҰϪºÃÒ¨éªk¡A¤£±o¦b¨S¦³µù¥U©Îµù¥U³B¾A¥ÎÁŧKªº±¡ªp¤U¦b¬ü°êµo°â©Î¥X°â |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/2/24 ¤U¤È 07:06:27
²Ä 5953 ½g¦^À³
|
2023-02-24 ASLAN Pharmaceuticals «Å¥¬§¹¦¨ Eblasakimab ªvÀø¯SÀ³©Ê¥Öª¢±wªÌªº 2b ´Á TREK-AD ¬ã¨sªº©Û¶Ò EblasaKimab ¦b¯SÀ³©Ê¥Öª¢ (TREK-AD) ¬ã¨s¤¤ªº¸ÕÅç¤w¸g©Û¶Ò¤F³Ì²×±wªÌ ¹wp¦b 2023 ¦~ 7 ¤ë¤W¦¯¤½§G³»½uµ²ªG ¥[§QºÖ¥§¨È¦{¸t°¨¯S¶ø©M·s¥[©Y¡A2023 ¦~ 2 ¤ë 24 ¤é¡]Àô²y·s»DªÀ¡^-- ASLAN Pharmaceuticals¡]¡§ASLAN¡¨¡A¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¡A¤@®aÁ{§É¶¥¬q¡B±Mª`©ó§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡ ¡A¤µ¤Ñ«Å¥¬¥¦¤w¸g¦b TREK-AD ¤¤©Û¶Ò¤F³Ì«á¤@¦W±wªÌ¡A³o¬O eblasakimab ¦b¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢¡] AD ¡^¦¨¤H¤¤ªº2b ´Á¾¯¶q½d³òÁ{§É¬ã¨s¡C ASLAN ¹wp±N¦b 2023 ¦~ 7 ¤ë¤W¦¯³ø§i³o¶µ¬ã¨sªº¥Dn¼Æ¾Ú¡C
ÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Ó¡B¾¯¶q½d³òªºÁ{§É¬ã¨s TREK-AD ©ó 2022 ¦~ªì±Ò°Ê¡A¥Hµû¦ô eblasakimab ¦b 16 ©PªvÀø´Á©M 12- ©P¦w¥þÀH³X´Á¡C ¸Ó¬ã¨s©Û¶Ò¤F¨Ó¦Û¥_¬ü¡B¼Ú¬w©M¨È¤Ó¦a°Ï 80 ¦hÓ¦aÂIªº±wªÌ¡C ¥DnÀø®Ä²×ÂI¬OÀã¯l±¿nÄY«µ{«×«ü¼Æ (EASI) µû¤À±q°ò½u¨ì²Ä 16 ¶gªº¦Ê¤À¤ñÅܤơC¦¸nÀø®Ä²×ÂI¥]¬A¹F¨ì¸gÅçÃÒªº¬ã¨sªÌ¥þ²yµû¦ô (vIGA) µû¤À 0¡]²M°£¡^©Î 1¡]´X¥G²M°£¡^ªº±wªÌ¤ñ¨Ò )¡BEASI ´î¤Ö 75% ©Î§ó¦hªº±wªÌ¤ñ¨Ò (EASI-75)¡B¹F¨ì EASI-50¡]´î¤Ö 50% ©Î§ó¦h¡^©M EASI-90¡]´î¤Ö 90% ©Î§ó¦h¡^ªº±wªÌ¤ñ¨Ò¡A¥H¤Î®pÈÅÜ¤Æ æ±Äoµû¤À¡C
¡§§ÚÌ«Ü°ª¿³¦b TREK-AD ¬ã¨s¤¤©Û¶Ò¤F³Ì«á¤@¦W±wªÌ¡A¨Ã´Á«Ý¦b 2023 ¦~ 7 ¤ë¤W¦¯¤À¨É³o¶µ«n¬ã¨sªº³»½uµ²ªG¡C³o¨Çµo²{±N§ó²M·¡¦a»¡©ú eblasakimab ªº®t²§¤Æ¡A¨Ãµ²¦X¥¿¦b¶i¦æªº TREK ¬ã¨sªº¼Æ¾Ú -DX ¬ã¨s¡A±N¤ä«ù¨ä§@¬° AD ±wªÌº¿ï¥Íª«»s¾¯ªº¼ç¤O¡A¡¨ASLAN Pharmaceuticals º®uÀç¾P©x Alex Kaoukhov ³Õ¤h»¡¡C ¡§§ÚÌ·PÁ°ѻP³o¶µ¬ã¨sªº©Ò¦³±wªÌ¡BÂå¥Í©M¸ÕÅç¬ã¨s¤Hû¡C ¥L̪º°Ñ»PÃÒ©ú¤F¹ïªvÀø AD ªº·sÀøªkªº»Ý¨D¡C¡¨
Ãö©ó eblasakimab
Eblasakimab ¬O¤@ºØ¼ç¦bªº¤@¬y³æ§J¶©§ÜÅé¡A¹v¦V 2 «¬¨üÅ骺 IL-13 ¨üÅé¨È°ò¡A³o¬OÅX°Ê¦hºØ¹L±Ó©Êª¢¯g¯e¯fªºÃöÁä³~®|¡C Eblasakimab ¿W¯Sªº§@¥Î¾÷¨î¯à°÷¯S²§©ÊªýÂ_ 2 «¬¨üÅé¡A¨Ã¦³¥i¯à§ï¶i¥Ø«e¥Î©óªvÀø¹L±Ó©Ê¯e¯fªº¥Íª«»s¾¯¡C ³q¹LªýÂ_ 2 «¬¨üÅé¡Aeblasakimab ªý¤î³q¹L¥Õ²ÓM¤¶¯À 4 (IL-4) ©M¥Õ²ÓM¤¶¯À 13 (IL-13) µo¥X«H¸¹¡X¡X¯SÀ³©Ê¥Öª¢ (AD) ª¢¯gªº¥DnÅX°Ê¦]¯À¡C 1b ´Á¦h¾¯¶q»¼¼W¬ã¨sªº¿n·¥µ²ªG¬° eblasakimab «Ø¥ß¤F·§©ÀÅçÃÒ¡A¨Ã¤ä«ù¨ä§@¬° AD ªº·s«¬®t²§¤ÆªvÀøªº¼ç¤O¡C ¨È·à±d¥Ø«e¥¿¦b¶i¦æ TREK-AD¡A³o¬O¤@¶µ 2b ´Á¸ÕÅç¡A¦®¦bµû¦ô eblasakimab ¦b¥Íª«ªìªv¤¤«×¦Ü««× AD ±wªÌ¤¤ªºÀø®Ä¡A¹wp±N©ó 2023 ¦~ 7 ¤ëªì¤½§Gµ²ªG¡C¨È·à±dÁÙ¦b¬ã¨s eblasakimab ¦b¸g¾ú¹L dupilumab ªº¤¤«×¦Ü««× AD ±wªÌ¤¤ªºÀø®Ä 2 ´Á¸ÕÅç TREK-DX ¤¤ªº±wªÌ¡A¹wp¼Æ¾Ú±N©ó 2024 ¦~²Ä¤@©u«×¤½§G¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/2/24 ¤U¤È 04:13:07
²Ä 5952 ½g¦^À³
|
½Ð°Ý TANG CAPITAL PARTNERS LPªº«ùªÑ5,364,925ªÑ(7.6922%)¬O¤T¤è¦@¦³¡C ¦Ó§ó¦ªº TANG CAPITAL MANAGEMENT LLCªº«ùªÑ5,364,925ªÑ(7.6922%)¬O¦Û¤v«ù¦³¡A¬O¶Ü??? ³o¼Ë TANG CAPITAL MANAGEMENT LLC¥»¨¦³¶W¹L15%ªºªí¨MÅv¡A¬O¶Ü??? ½Ð±Ð¦U¦ì¤j¤j. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2023/2/23 ¤U¤È 09:56:58
²Ä 5951 ½g¦^À³
|
ªü´µÄõ»sÃÄ31.6%ªºªÑ¥÷¥Ñ¾÷ºc§ë¸êªÌ«ù¦³¡C ªü´µÄõ»sÃÄ4.7%ªºªÑ¥÷¥Ñ¤½¥q¤º³¡¤H¤h«ù¦³¡C ±j¤jªº¾÷ºc«ùªÑªí©ú¡A¤j«¬°òª÷ºÞ²z¤½¥q¡B®½ÃØ°òª÷©M¹ï½Ä°òª÷¬Û«H¡A¤@®a¤½¥q¦³±æ¹ê²{ªø´Á¼Wªø¡C ¡ãMarketBeat.com. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2023/2/22 ¤U¤È 03:57:31
²Ä 5950 ½g¦^À³
|
§Ú°O±o¦³¤@±ø³W©w¡A¬O¥i¥H©µªø¤é´Á ªº¤U¥«³W©w¡A¤£µM³Ì«á¥i¯à¨«¦V´î¸ê³o±ø¸ô ¤½¥q¦³¦b¥«³õÄw¸êªº¶·¨D¤£·|»´©ö¤U¥« |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/22 ¤U¤È 02:28:12
²Ä 5949 ½g¦^À³
|
³¯¤j¡B ¤£¬ÝªÑ»ù¡B©ñ¸2¤@3Ó¤ë¡D ¤@¤ÁÀH½t!
©ÎªÌ¤£ºÞ¥¦¦³¸Ñª¼º¦10¿¼ç¤O¡B½æ±¼¥¦¡D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/2/22 ¤U¤È 01:50:18
²Ä 5948 ½g¦^À³
|
¤Ñ©R¤j
¦Ü3¤ë26¤é¶È³Ñ1Ó¤ë
¨È·à±dÁÙ¦³¤°»ò¤èªk¥i¦Û±Ï¡A °£¤F´î¸ê©Î¤U¥«¤èªk¥~¡A
§Ú«ç»òı±o³o®a¤½¥q©R¹B¦h¦ß
¹B®ð«D±`¤£¨Î¡A
ÁÙ¬O¯à¤O¤£¨¬¡A¤H¿Ñ¤£»N
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/2/22 ¤W¤È 08:05:40
²Ä 5947 ½g¦^À³
|
¬Q±ß¤j¶^«á¡A·à¤l¦b¤T¤ë©³«e¯¸¤W1¬ü¤¸Ãø«×§ó°ª¤F ¦^·Q¨â¦~«e228³s°²¡A·à¤l¨g¼Qªº¼Ò¼Ë¾ú¾ú¦b¥Ø ¤µ¦~228¡A·à¤l¯àµ¹¤j®a¤@Ó°ª¼é¶Ü? ¤£³Ó®D¼N... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/21 ¤W¤È 08:53:11
²Ä 5946 ½g¦^À³
|
REGN ¤½¥q ²¤¶¡þ2023¦~¤G¤ë
investor.regeneron.com/static-files/ff73fc12-062d-41c2-8ca4-98d63f3bcf49
1¡ADupilumab ¦b2022¦~¨ú±o5ÓFDAªº«¬IIª¢¯g¡C¬ÛÃöÃįg¡C 2¡ADupilumab ¦b2022¦~¦~¾P87»õ¬ü¤¸¡C¡]¥þ¤½¥q¦¬¤J¬ù200»õ¬ü¤¸¡Aµ|«e²b§Q¬ù60%¡^
3¡AREGN 2023¦~±N§ë¤J43»õ¬ü¤¸¬ã¨s¶O¥Î¡C
4¡A2019¦~¨Ó®w¦sªÑ¬ù¶R¦^10»õ¬ü¤¸ 5¡B2023¦~¤G¤ë«Å¥¬¥t¥~±N¶R¦^®w¦sªÑ30»õ¬ü¤¸¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/19 ¤W¤È 08:43:06
²Ä 5945 ½g¦^À³
|
¦Xx ±ÂÅvFB825 .¦¬²{ª÷10»õ¥x¹ô ªÑ»ù¥Ñ30¤Wº¦¦Ü140¤¸¡B¥«È¼W¥[°_¹L400»õ(13»õ¬ü¤¸)
¦p¤µ FB825 p¹º°µ¾ô±µSCÁ{§É(¤w°±13Ó¤ë)¡B2bÁ{§É 预p2024¦~¶}©l¡D
¤w¸¨«áASLAN004 2bÁ{§É2¦~¡D
ASLAN004 2b ¤»¤ë©³¸Ñª¼¡B Y¦p预´ÁIGA0,1>44%vs 15%(¹ï·Ó组)
³Ì°ª¨é°Ó¥Ø¼Ð»ù7¬ü¤¸¡D ¶Ò¸ê»ù7*80%=5.6¬ü¤¸¡D 5.6x7¸U¤dªÑADR=4.92»õ¬ü¤¸
µo¦æªÑ±N¹F15¸U¤dªÑ
15x5.6=8.4»õ¬ü¤¸(¥«È)¡D ¥H¤W¤è¬O¬O2b§¹¦¨ AD °ê»Ú¦æ±¡¡D(DERM §¹¦¨2b ¡B¤½§G¶Ò¸ê«á7.5»õ¥«È)
ASLAN004 ¦bAD ¤w§¹¦¨·§©À©ÊÁ{§É(1b ITT¤À§é) ¦b²Îp¤W¦³©úÅã©M¹ï·Ó组¦³©úÃD®t²§¡D N=22v16 p=0.01
FB825 2a ADÁ{§ÉN=99 ¥¼³q¹L统pÀË©w¡Dp>0.05
ªÑ»ù¦p¦Ñ¤H²oªºª¯¡B¶]¤W¶]¤U¡B²×¦³¤@¤é¦^À³¦³»ùÈ¡D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2023/2/18 ¤U¤È 02:47:13
²Ä 5944 ½g¦^À³
|
¤U¥«±N¦Ü¡A¥H¥Ø«e»ù®æ0.8¤¸¨Ó»¡¡AYn¦b¤U¥««e¼W¸ê¡A¥²¶·µo¥¬«¤j§Q¦h©Î¤½¥¬´Á¤¤³ø§i©Ô©ïªÑ»ù«á¤~¦³¼W¸êªº·N¸q¡A¤£µM´N¥u¯à¾a´î¸êºû«ùªÑ»ù¨ÓÁקK¤U¥«¡A¦Ó¥B»Ýn¦b0326«e³sÄò10¤Ñ»ù®æ°ª©ó1¤¸¡A¦ý¥H2023¦~0.4~0.8»ù®æ°Ï¶¡¨Ó»¡¡A§Y¨Ï´î¸ê¤¦¨»ù®æ¦^¤É¨ì1.6¤¸¡A¤]Ãø«O¤£·|¦b0313~0326¤§¶¡³Q¥´¤U1¤¸¤´n°h¥«¡A¹ï§Ú¨Ó»¡¡A°µ¤£¨ìµo¥¬«¤j§Q¦h©Î¤½¥¬´Á¤¤³ø§i©Ô©ïªÑ»ù¡A¶È¾a´î¸êºû«ù¦í¤W¥«¸ê®æ¡AºÞ²z¼h´N¤w¸gÅý¤HµLªk±µ¨ü¤F¡A±q¦¬¨ì°h¥«§ïµ½³qª¾¨ì²{¦b¡A¾ã¾ã¤@¦~¹L¥h¡AºÞ²z¼hªº§@¬°¦bþ?(20210301¬°¤FÄw¿ú¼W¸ê¡A¥i¬O³s¤@´ÁÂX¼W¸ÕÅç¤~è¶}©l¡A¦bÁ`¦¬®×¤H¼Æ18¤H¡Aç°£«á¹êÅç²Õ9¤H¡A¹ï·Ó²Õ5¤Hªº±¡ªp¤Uµo¥¬´Á¤¤³ø§i)ÁöµMASLANn°_¦º¦^¥Í¯uªº»Ýn2B¸Ñª¼¦¨¥\¡A¤£µM´N¬OÅܦ¨¾À¯È¡A¦ý¦b¦³®É¶¡À£¤Oªº±¡ªp¤U¡AºJ¶}004¦¨±Ñ»P§_¤£»¡¡A²{¦b³s´Á¤¤³ø§i³£¨S¦³¡A³oºÞ²z¼h¯uªº¥i¥HÅý¤H«HªA? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/2/17 ¤U¤È 08:24:31
²Ä 5943 ½g¦^À³
|
3/26¶V¨Ó¶Vªñ ·à¤lªÑ»ù¥Ø«eÁÙ¦b0.8©â´¡ ¦Ñ¹êÁ¿¥un¤½¥q¬£¦³¤ß±À¤W¥h1¬ü¤¸´X¤Ñ¡A¸Ñ°£¤U¥«¦M¾÷À³¸Ó¤£Ãø §Æ±æ·à¤l¤£n·d´î¸êµ}ÄÀ³o®M |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/2/17 ¤U¤È 05:24:13
²Ä 5942 ½g¦^À³
|
Yn´î¸ê©Î°f¤À³Î¡A¦b¤W¦¸ªºÂX¼WªÑ¤ÀªÑªF·|´N·|¤@¨Ö°Q½×¤F
¦P·N+1 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2023/2/17 ¤U¤È 04:46:26
²Ä 5941 ½g¦^À³
|
Yn´î¸ê©Î°f¤À³Î¡A¦b¤W¦¸ªºÂX¼WªÑ¤ÀªÑªF·|´N·|¤@¨Ö°Q½×¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2023/2/17 ¤U¤È 04:42:21
²Ä 5940 ½g¦^À³
|
¦b¤U¤ñ¸û¼ÖÆ[ »{¬°ªÑ»ù±q¥´©³¶¥¬q¡A¥¿´Â1¬ü«e¶i¡I Ä~Äò¬ÝÀ¸¡I
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/17 ¤U¤È 04:01:32
²Ä 5939 ½g¦^À³
|
¿éŦb2bªº¼Æ¾Ú
IGA0/1,>44%vs15%(¹ï·Ó²Õ)
³Q¨ÖÁÊ»ùȨӦۤWz2b¼Æ¾Ú¡G
资¥»ÂX¥R§Ö³t¦]¤waslan001ªº¥¢±Ñ¦¨¥»¡D
Derm lebrikizumab 2b¸Ñª¼¦¨¥\¡B¶Ò¸ê«á¡B¥«È¬ù7.5»õ¬ü¤¸¡B³Ì«á11»õ¬ü¤¸³Q¨Ö¡D
Ó¤H²`«H¤£·|¤ñDERM§ó®t¡D
§Ú̦b²Ä8¶g®ÉªºIGA0.1¥i¬O 44%vs30%(lebr.)ªºÁͶաD
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2023/2/17 ¤U¤È 03:42:39
²Ä 5938 ½g¦^À³
|
¤£¿Ð¨¥¡A´î¸ê´N¬O¹ï¤j³¡¥÷²{¤µ«ùªÑ§ë¸ê¤H³Ì¤jªº¶Ë®`!!! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2023/2/17 ¤U¤È 03:41:35
²Ä 5937 ½g¦^À³
|
²{¦b¬Ý¨ìªº¬O2022/12/31ªº«ùªÑ¡A 2022Q4 10/2-12/31 ±q0.586¡÷0.435 2023¨ì²{¦b¡A±q0.435¡÷0.8 n¬O¨S¦³¯S¦nªº¼Æ¾Ú¡A³»¦h´N³o¼Ë¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/17 ¤U¤È 02:03:22
²Ä 5936 ½g¦^À³
|
Y¬O´î¸ê50%«á¡B¶Ò¸ê»ùÁÙ¬O7x80%=5.6¬ü¤¸
³o¥Nªí¤½¥q¤]»{¬°ASLAN004ªºÄvª§¤O¤£¬O³»±j¡D
³Q¨ÖÁÊ»ù¦ÛÀ³¤j´T¤UסD |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/17 ¤U¤È 01:52:41
²Ä 5935 ½g¦^À³
|
¤@¡B°²³]´î¸ê50% ´î¸ê«á¥Ø¼Ð»ù14¬ü¤¸ ¶Ò¸ê»ù14x80%=11.2¬ü¤¸/ADR
¤G.°²³]¤£´î¸ê ¥Ø¼Ð»ù7¬ü¤¸ ¶Ò¸ê»ù7x80%=5.6¬ü¤¸
¥¼¨Ó¤T´Á16¶g¸Ñª¼¦ô¦b2025¦~©³¡D ¤~¦³¥i¯à¦A¶Ò¸ê¡D
¦b¥ÃÁZ经À窺¦Ò¼{¤U¡D
¨º¤@Ó¤è®×¤ñ¸û¤£·|¨Ï¥¼¨Ó2026¦~¶Ò¸ê«eªÑ»ù¤S§C©ó¤@¬ü¤¸?
§Ú¬O¤ä«ù´î¸ê¡D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2023/2/17 ¤U¤È 01:13:23
²Ä 5934 ½g¦^À³
|
ªoºj¤j»¡±o¨S¿ù¡A¥H¦¹¦¸¾÷ºcªk¤Hªº«ùªÑ¨Ó¬Ý¡AÁ`¬A¨Ó¬Ýªº½T¬O½æ¥X¤j©ó¶R¶i¡A§Æ±æ3/26«e¯à¦³¯¸¤Wªº¨M¤ß¡F¤£µM´N¥u¯à¬O¥D¨ÆªÌ¥i¯à·QÅý¤½¥q´î¸ê¡AµM¦A§C»ù¼W¸ê¡A¶i¦Óµ}ÄÀÅv«¤jªº¨È¬w«ùªÑ¡C
¥H¤W¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2023/2/16 ¤U¤È 09:26:37
²Ä 5933 ½g¦^À³
|
¤Ú§JµÜ¦³¤½¥q¦bªü´µÄõ»sÃĦ³¤½¥q¡]¯Ç´µ¹F§J¡Gªü´µÄõ¡^¾Ö¦³ 283,000 ¬ü¤¸ªºªÑ²¼±±ªÑÅv ®Ú¾Ú¨ä³Ìªñ¦VÃÒ¨é¥æ©ö©eû·|¡]SEC¡^´£¥æªº¤å¥ó¡A¤Ú§JµÜ¦³¤½¥q¦b²Ä¤T©u«×«d´î¤F¨ä¦bªü´µÄõ»sÃĦ³¤½¥q¡]NASDAQ¡GASLN-Àò±oµû¯Å¡^ªºªÑ¥÷¦ì¸m 7.4¢H¡C¦b´Á¤º¡A°òª÷¦b½æ¥X 37,694 ªÑªÑ¥÷«á¾Ö¦³¸Ó¤½¥qªÑ²¼ªº 471,270 ªÑªÑ¥÷¡C¤Ú§JµÜ¤½¥q¾Ö¦³ 0.68¢H ªºªü´µÄõ»sÃÄ»ùÈ 283,000 ¬ü¤¸¦b³Ìªñ¤@Ó©u«×µ²§ô®É¡C ¨ä¥L¾÷ºc§ë¸êªÌ©M¹ï¨R°òª÷¤]¶R½æ¤F¸Ó¤½¥qªºªÑ²¼¡C¤dÁHºÞ²z¦³³d¥ô¤½¥q¦b²Ä¤G©u«×±N¨ä¦bªü´µÄõ»sÃĪº«ù¦³¶q´£°ª¤F 2.8%¡C¤dÁHºÞ²z¦³³d¥ô¤½¥q²{¦b¾Ö¦³¸Ó¤½¥qªº 1,613,113 ªÑªÑ²¼¡A»ùȬ° 804,000 ¬ü¤¸¡A¦b¦¹´Á¶¡ÃB¥~ÁʶR 43,949 ªÑªÑ²¼«á¡C¬ü°ê»È¦æ¤½¥q DE ¦b²Ä¤@©u«×¼W¥[¤F 34.4% ¦bªü´µÄõ»sÃĪº¦a¦ì.¬ü°ê»È¦æ¦b¤W¤@©u«×ÃB¥~ÁʶR 66,544 ªÑªÑ²¼«á¡A²{¦b¾Ö¦³¸Ó¤½¥qªÑ²¼ªº 259,722 ªÑ»ùÈ 233,000 ¬ü¤¸¡C¤åÃÀ´_¿³¬ì§Þ¦³³d¥ô¤½¥q¦b²Ä¤@©u«×¦¬ÁʤFªü´µÄõ»sÃĪº·s¦ì¸m $64,000.³Ì«á¡ADAFNA ¸ê¥»ºÞ²z¦³³d¥ô¤½¥q¦b²Ä¤G©u«×±N¨ä¦bªü´µÄõ»sÃĪº¦a¦ì¼W¥[¤F 41.0%¡CDAFNA ¸ê¥»ºÞ²z¦³³d¥ô¤½¥q²{¦b¾Ö¦³¸Ó¤½¥qªÑ²¼ 343,720 ªÑ¡A»ùÈ 17 ¸U¬ü¤¸¡A¦b¤W¤@©u«×ÃB¥~ÁʶR¤F 100,000 ªÑ¡C¾÷ºc§ë¸êªÌ©M¹ï¨R°òª÷¾Ö¦³¸Ó¤½¥qªÑ²¼ªº 31.59¢H¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2023/2/16 ¤U¤È 02:23:19
²Ä 5932 ½g¦^À³
|
»P¨ä¬Ýºô¯¸¾ã²zµ²ªG¡A¬ÝSEC©x¤è¤å¥ó¤ñ¸û·Ç½T¡A¤å¥ó«Ü²M·¡¼g©ú¦@¦P¤À¨É26,824,625ªÑ´¶³qªÑ(¦@5,364,925ªÑ ADS)¡A©Ò¥H¤Gªk¤H+¤@Ó¤H¦Xp«ùªÑ5,364,925ªÑADS¥eASLANÁ`«ùªÑ7.8%.......¡A¤ñ¸û¥O¤H¦b·Nªº¬O쥻«ù¦³ªÑ¼Æ¤]¤£¤ÖªºRTW Investments,¤w¸g¥X²M«ùªÑ¤F......¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/2/16 ¤U¤È 01:39:58
²Ä 5931 ½g¦^À³
|
𤽥q¤£¯Ê¿ú¡A¥i¯àªº¨Mµ¦¬OÅý¨È·à±d°µ§¹¤T´ÁÁ{§É«á¡A¥H§ó°ª»ù¿ú³Q¨ÖÁÊ¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/2/16 ¤W¤È 10:40:34
²Ä 5930 ½g¦^À³
|
³oÓºô¯¸(www.nasdaq.com/market-activity/stocks/asln/institutional-holdings) ¨q¥Xªº«ùªÑ²Ä¤@¦W¬OTANG CAPITAL MANAGEMENT LLC«ùªÑ¨È·à±d5,364,925 ªÑ (¨S¨q¥XTANG CAPITAL PARTNERS LP«ùªÑ)
¦Ó³oÓºô¯¸(whalewisdom.com/stock/asln) ¨q¥Xªº«ùªÑ«e¨â¦W¾÷ºc¤À§O¬O 1.TANG CAPITAL PARTNERS LP«ùªÑ¨È·à±d26,824,625ªÑ 2.TANG CAPITAL MANAGEMENT LLC«ùªÑ¨È·à±d5,364,925 ªÑ
¦ÓTANG CAPITAL PARTNERS LP´N±q¥h¦~²Ä¤T©u¹s«ùªÑ´£¤É¨ì²Ä¥|©u«ùªÑ26,824,625ªÑ ±qwhalewisdom.com/stock/asln¸Óºô¯¸²Ä9¦æ(% Ownership)Åã¥Ü TANG CAPITAL PARTNERS LP(% Ownership)¬O38.4612% TANG CAPITAL MANAGEMENT LLC(% Ownership)¬O7.6922% TANG CAPITAL PARTNERS L©MTANG CAPITAL MANAGEMENT LLC¬O¦P¤@Ó¦ÑÁó ¦ÑÁó«À£¨È·à±dµL»~¡C
ɥΤѩR¤j¡G ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2022/9/29 ¤W¤È 11:43:48 Tang ¸ê¥»ºÞ²z¤w¨ú±o5555¤dªÑ¡Aªñ8%¡A µ´¹ï¦³¯à¤O¼vÅT¤½¥q¨Mµ¦¡C
TANG CAPITAL PARTNERS LP¦³38.4612% ¨º¤£´N·Ç³Æ®³¤U¨È·à±d¨Mµ¦Åv???
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/15 ¤U¤È 07:01:14
²Ä 5929 ½g¦^À³
|
Tang Capital Partners. Tang Capital Partners beneficially owns 26,824,625 Ordinary Shares of the Issuer, in the form of 5,364,925 ADSs. Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang. Tang Capital Management. Tang Capital Management beneficially owns 26,824,625 Ordinary Shares of the Issuer, in the form of 5,364,925 ADSs. Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang. Kevin Tang. Kevin Tang beneficially owns 26,824,625 Ordinary Shares of the Issuer, in the form of 5,364,925 ADSs.
ð¸ê¥»¦X¹Ù¤H¡C Tang Capital Partners ¹ê¯q¾Ö¦³µo¦æ¤H 26,824,625 ªÑ´¶³qªÑ¡A§Î¦¡¬° 5,364,925 ¬ü°ê¦s°U¾ÌÃÒ¡C Tang Capital Partners »P Tang Capital Management ©M Kevin Tang ¤À¨É¹ï³o¨ÇªÑ¥÷ªº§ë²¼Åv©M³B¸mÅv¡C ð¸ê¥»ºÞ²z¡C Tang Capital Management ¹ê¯q¾Ö¦³µo¦æ¤H 26,824,625 ªÑ´¶³qªÑ¡A§Î¦¡¬° 5,364,925 Ó¬ü°ê¦s°U¾ÌÃÒ¡C Tang Capital Management »P Tang Capital Partners ©M Kevin Tang ¦@¨É¹ï³o¨ÇªÑ¥÷ªº§ë²¼Åv©M³B¸mÅv¡C ð³Í¤å¡C Kevin Tang ¥H 5,364,925 ªÑ¬ü°ê¦s°U¾ÌÃÒªº§Î¦¡¹ê¯q¾Ö¦³µo¦æ¤Hªº 26,824,625 ªÑ´¶³qªÑ¡C
ir.aslanpharma.com/static-files/ba66da24-32ee-49f4-b6eb-b181b975a000
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2023/2/15 ¤U¤È 06:09:33
²Ä 5928 ½g¦^À³
|
¸Ø±i¤j¡A±zªºªÑ¼ÆÁÙn°£¥H¤¡A¥i¯àn¦A½T»{¤@¤U~¥H¤Uºô¯¸¨Ñ°Ñ
www.nasdaq.com/market-activity/stocks/asln/institutional-holdings |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/2/15 ¤U¤È 05:25:37
²Ä 5927 ½g¦^À³
|
¥h(111)¦~²Ä4©u«ùªÑ¨È·à±d§ë¸ê¾÷ºc«e2¦W 1.TANG CAPITAL PARTNERS LP«ùªÑ¨È·à±d26,824,625ªÑ(¦û38.4612%) 2.TANG CAPITAL MANAGEMENT LLC«ùªÑ¨È·à±d5,364,925 ªÑ(¦û7.6922%) 𤽥q«À£¨È·à±d46.1534% ¦U¦ì¤j¤j¦³¦ó¬Ýªk???
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/15 ¤W¤È 06:50:20
²Ä 5926 ½g¦^À³
|
¤Úµá¯S²Ä¥|©u½æ±¼86%ªº¥x¿n¹q«ùªÑ¡B¥Ø«e«ùªÑ¹s¦¨¥»¡D
·Q¤£¨ì! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/10 ¤U¤È 12:05:01
²Ä 5925 ½g¦^À³
|
ASLAN004¤@½uÀø®Ä预«h
400mg*Q2w >300mg*Q2W>600mg*Q4W>400mg*Q4W
®Ú¾Ú¡G Dupilumab/Lebrikizumab 2´ÁÀø®Ä
IGA0,1¡G4¶g¤@针/2¶g¤@°w=70%¥ª¥k EASI75¡G4¶g¤@针/2¶g¤@针=93%
¥¼¨ÓASLAN004ªº¥|¶g¤@°w¡B¤T´ÁÁ{§É¡BÀ³¦pLebr¡D¥u¥Î¦b17~52¶gªº©µ¦ùÁ{§É¡D
©Ò¥H¤T´ÁÁ{§É³]p¥i¯à¦pLebr. AD¤T´Á ¾÷·|°ª¡D 400mgx2¶g¤@°wx16¶g ©M¹ï·Ó组(2¡G1)¡B¦@400¤H¡D ¶·2Ó3´Á¦@800¤H¡D
¥t°µ17-52¶g©µ¦ùÁ{§É¡D
²Ä¤TÓ¤T´Á¬°PK TCS¬ù250¤H¡D
¦Ü©ó¤G½u¤T´Á¡BLebr.¥u°µ120¤Hªºopen Lebvbl.¨S¹ï·Ó组¡D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/10 ¤W¤È 11:20:48
²Ä 5924 ½g¦^À³
|
Æ[¹î
ASLAN004 ADªº¤G½u¥ÎÃÄÁ{§É ±Ä¨C¶g¤@°wx16°wx400mg 600mg/600mg/400mg...400mg
®Ú¾Ú¥h¦~9¤ë15¤éR&D ¤é ¤½¥q»{¬°¹w´ÁÀø®Ä¨¬¥H©M¤fªAÃĪ«(JAK§í¨î¾¯¡BIGA0,1=55%-60% ¬Û·í¡D
Dupilumab ¤T´Á´¿¦P®É°µ¡B¨C¶g¤@°w/¨C¤G¶g¤@°w¡B¦Ó¥LÌ16¶gªvÀøIGA0,1Àø®Ä©M¹ï·Ó组®t²§¬Ò¦P¬°28%.
IGA0,1=53%~65% vs15%(¹ï·Ó组) ®t²§38%~50%
vs Dupilumab 28% IGA0,1Àø®Ä =38%/28%=135% ~ =50%/28%=178%
ASLAN004¦b¨C¶g¤@°w¤W¤@¦³Àu©óDupilumab
35%~78%ªº预´ÁÀø®ÄÁͶÕ
YASLSN004¤@½u©MDupilumab Àø®Ä®t²§¤£¤j¡D
¥Ñ©ó¦b¤G½u¤Wªºµ´¨ÎªºÀø®ÄÀu¶Õ¡D ¥iÀ°§U¤@½uªº销°â¡D
¥H¤W§Y¬O¤½¥q³ø§i©Ò»¡ªº¼Æ¾Ú¼ÒÀÀ¡D
¼W¥[¤@½u°¾¦n¡B§Y¼W¥[³Q¨ÖÁÊ»ùÈ¡D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GDHL10147526 |
µoªí®É¶¡:2023/2/8 ¤U¤È 09:58:44
²Ä 5923 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/2/8 ¤U¤È 08:54:19
²Ä 5922 ½g¦^À³
|
ªÑ»ù¶Z1¬ü¤¸¤w¤£»· §Æ±æ¥i¥H¦b3¤ë«e¯¸¤Wªü |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2023/2/8 ¤U¤È 05:30:39
²Ä 5921 ½g¦^À³
|
Aslan Pharmaceuticals Receives Decision to Grant European Patent Titled ¡¦MALONATE SALT OF VARLITINIB (FOR THE TREATMENT OF CANCER)¡¦ ªü´µÄõ»sÃĤ½¥qÀò±o±Â¤©¼Ú¬w±M§Qªº¨M©w¡A¦W¬°¡u¥ï§Q´À¥§ªºÄ«ªG»ÄÆQ¡]¥Î©óªvÀøÀù¯g¡^¡v |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/2/8 ¤U¤È 03:58:51
²Ä 5920 ½g¦^À³
|
Aslan Pharmaceuticals ¦¬¨ì±Â¤©¦W¬°¡§¤þ¤G»Ä´À¥§ªº¤þ¤G»ÄÆQ¡]¥Î©óªvÀøÀù¯g¡^¡¨ªº¼Ú¬w±M§Qªº¨M©w
Aslan Pharmaceuticals Receives Decision to Grant European Patent Titled ¡¦MALONATE SALT OF VARLITINIB (FOR THE TREATMENT OF CANCER)¡¦ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/8 ¤U¤È 02:15:23
²Ä 5919 ½g¦^À³
|
003 ¥i¯à¦åÀùÁpÃÄ¡H ¤£ª¾´X½u¡H¥¼¨£Á{§É¸ê°T¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¿ûÅK¨k¤l10144826 |
µoªí®É¶¡:2023/2/8 ¤U¤È 01:11:37
²Ä 5918 ½g¦^À³
|
register.epo.org/application?number=EP19790887 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¿ûÅK¨k¤l10144826 |
µoªí®É¶¡:2023/2/8 ¤U¤È 01:06:06
²Ä 5917 ½g¦^À³
|
register.epo.org/application?number=EP19790887001
001«±Ò¶Ü? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2023/2/6 ¤U¤È 11:41:44
²Ä 5916 ½g¦^À³
|
²{¦b»ù®æ0.755 ¦b¥[¤@§â«l 1¬ü «Ü®e©ö¹F°} »ô¤ß¦X¤O¿ÂÃƯë¤j¶H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/3 ¤U¤È 09:21:20
²Ä 5915 ½g¦^À³
|
Dupilumab/Dupixent 2022¦~Q4°]³ø¥XÄl ¬°24.5»õ¬ü¤¸¡A
2022¦~À禬²Öp86.8»õ¬ü¤¸¡A¦ô2023¦~À禬¯}¦Ê»õ¬ü¤¸¡C
³æ¦ì:¦Ê¸U¬ü¤¸ USA(¬ü°ê)// ROW (¨ä¥L°Ï°ì)//¤pp
2022 Q1 1,325.6//484.8//1,810.4 Q2 1,582.1//509.7//2,091,8 Q3 1,824.0//506.1//2,330.1 Q4. //2,450.0 ¦Xp¡C //8¡A682 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2023/2/2 ¤W¤È 09:25:03
²Ä 5914 ½g¦^À³
|
¤d¸U¤£n¦³°f¤À³Îªºª¬ªpµo¥Í¡A§Y¨Ï¤À³Î§¹«á¥«È¤£ÅÜ¡A¦ýªÑ²¼¬O¨C¤Ñªi°Ê¡A¸gÀçÆ[©Àª¬ªp®t¡AÁÙ·|¦A¦^¶^¨ì1¶ô¥H¤U¡A©Ò¥Hªü«i¤U¥x¤~¬O¸Ñ¤è¤§¤@¡AÅý»{¯u¸gÀçªÑ»ùªºCEO¤W¥x¥D«ù¡A¦¨¥\¸Ñª¼±a°ÊªÑ»ù¦^¨ì¥¿±`¡A¤~¬O¥¿¹D¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/2 ¤W¤È 08:31:08
²Ä 5913 ½g¦^À³
|
¦pªG3¤ë25¤éªÑ»ù¥¼¹F¤@¬ü¤¸¡A±N°õ¦æ°f¤À³Î¡C
°²³]²{¦³ªÑ²¼5ªÑ¡]ì©lªÑ¡^´«1ªÑADR¡AÅܧó¬°10ªÑ¡]ì©lªÑ¡^´«1ªÑADR¡C
«hì¥ý¤wµo¦æADR¡Aªñ7¸U¤dªÑÅܦ¨3¸U5¤d¤dªÑADR¡C
¨CӪѪF«ùªÑ´î50%¡C
Y6¤ë©³¸Ñª¼¦¨¥\¡A²Å¦X¹w´Á¡A¨º¥Ø¼Ð»ù´N¥Ñì¥ý7¬ü¤¸¡Aº¦¤@¿¨ì14¬ü¤¸¤F¡C
7¬ü¤¸X7¸U¤dªÑ=4»õ9¤d¸U¬ü¤¸¡K¡K¥Ø¼Ð¥«È
°f¤À³Î«á¥Ø¼Ð¥«È4»õ9¤d¸U¬ü¤¸¤£·|ÅÜ¡C
ªÑ¥»´î¬°¤@¥b3¸U5¤d¤dªÑADR
4¡P9»õ¬ü¤¸¡þ3¡P5¸U¤dªÑADR=14¬ü¤¸¡þªÑ¡C
µ²½×¡G°f¤À³Î¤£·l¥«È¡A«ÂI¦b¸Ñª¼Àø®Ä¬O§_¶W¥X¡þ²Å¦X¹w´Á¡C
IGA0¡A1>44%¡]¹ï·Ó²Õ15%¡^ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/2/2 ¤W¤È 12:35:52
²Ä 5912 ½g¦^À³
|
¤Ï¥¿²{¦b½æ¤]®³¤£¦^¤°»ò¿ú ¤£¦p´N¤ß¥®ð©M¬Ý¤½¥q«ç»òª± ³ÌºC¤T¤ë©³¤]´Nª¾¹DÓ¤j·§(¬Ý«ç³B²z¤U¥«°ÝÃD) ¦Ñ¸Ü¤@¥y¡A¤j®a°µ¦nÃz±¼·Ç³Æ´N¬O¡A¦¨¥\ºâ¤¤¼Ö³z |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/1 ¤U¤È 06:37:16
²Ä 5911 ½g¦^À³
|
¥h¦~10¤ë28¤éªº²Ä¤T©u°]³ø¤w§iª¾²Ä¤G©u¤½¥¬004 2b Topline data(¸Ñª¼³ø§i).
¤½¥q¦³¨Í§ï¶iªº¬O clinicaltrials.gov/ct2/show/NCT05158023 ºô¯¸¤Wªº ¹w¦ô¤é´Á没¦³ÀH¤§§ó°Ê,¥O¤H¤£ª¾ÁÙ¦³¤@§åªñ20%¥¼°µ.
³¯¤j駡ªº¦³²z.
Anticipated upcoming milestones • First patient enrolled in the TREK-DX trial by the end of 2022. • New translational data highlighting the unique effects of eblasakimab¡¦s mechanism of action will be presented in early 2023. • Topline data from the Phase 2b TREK-AD trial of eblasakimab is expected in Q2 2023.
ir.aslanpharma.com/static-files/b0ccbacc-0751-41fc-a55c-dee886e7e797 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/1 ¤U¤È 06:18:19
²Ä 5910 ½g¦^À³
|
¦pªG¶Ò¸ê¶Ò¤£¨ì¦pCNBC¡AªÑ»ù¶È¶W¹L¤@¬ü¤¸¡A¨º»ùÈ´N«Ü§C«Ü§C¡C
²{¦b¥«È¤£¨ì5¤d¸U¬ü¤¸¡C
¶·¶Ò4»õ¬ü¤¸¡C
¤ýµPY½¯à¶Ò4»õ¬ü¤¸¡A¤~·|½¡C°µ¤T´Á¤~°÷¡C
´Nµ¥¤½¥q¯à¥X¦óºØµP¡H
ASLNªºCE0«ùªÑªñ5%¡A§ÚÁÙ¬O¤£¬Û«H·|´î¸ê¦Û¬å²Â³J¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/2/1 ¤U¤È 05:29:47
²Ä 5909 ½g¦^À³
|
³o®a¤½¥q§@¬°´N¬O²@µL¸Û«H¥i¨¥¡A«Ü·|ÄF
¤Ï¤Z¨ÆÁ׫´N»´
§Ú²{¦b´N¬O¨C¤Ñ¸ò¥¦EMAIL ½Ð¦w°ÝÔ
¥H¬ª¼« |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gªoºj·Æ±¼10153108 |
µoªí®É¶¡:2023/2/1 ¤U¤È 05:05:59
²Ä 5908 ½g¦^À³
|
³£§Ö¤U¥«¤F¡A§ÚÁÙ¤`µPù¡A´Nºâ´î¸êÀ±¸ÉÁ«·l¸ú¹L¤U¥«¡A§A¦U¦ì¤§«á¨p¶Ò¡B¨é°Ó¥]¾P¤]¨S¥÷¡A´Nºâ¸Ñª¼¦¨¥\¡A´î¸ê«á¤â¤¤«ùªÑ¤S³Ñ¦h¤Ö?§ó¹N½×¸Ñª¼¦³¥¢±Ñ¥i¯à¡A¦Ó¥B1/30¥[¶}¦¬®×¤¤¤ß¾ãÅé®Éµ{©µ«á¡AÃø¹D1/6§ó·s¤½¥q²³øªº®ÉÔ¤½¥q¤£ª¾¹D?§Ú¬ÝÁÙ¬O«Ü¼ÖÆ[¹wpQ2¼Æ¾Ú¥X¨Ó°Ú¡A³o®a¤½¥qµ¹¤Hªº·Pı´N¬O¤£¦Ñ¹ê¡A¤j·§·|¨«¦V¥xÆWµL¨}¤½¥q´î¸ê¦A¼W¸êªº¸ô½u¡A§Y¨Ï³Ì«á¦¨¥\¡A즳ªÑªF¤]¤À¤£¨ì¤°»ò¦n³B¡A¨Ó¬Ý¬Ýµ²ªG·|¤£·|¥´§ÚÁy¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/1 ¤W¤È 10:46:33
²Ä 5907 ½g¦^À³
|
¸Ø±i¤j ,
´Á¤¤³ø§i¬O¤ýµP.
©Ò¦³¤§«e¦ôp¶Ò¸ê®Éµ{·|©µ«á2~3Ó¤ë.
6¤ë©³2b ¤@½u¸Ñª¼
6¤ë©³2b¤G½u¤j¬ù¥i¤½§G´Á¤¤³ø§i(39¤H).
¥i¼W¥[¨C¶g¤@°w*16¶gªº¤G½u³Q¨Ö»ùȦôºâ.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/2/1 ¤W¤È 10:30:07
²Ä 5906 ½g¦^À³
|
·s¼W18Ó¦¬®×¤¤¤ß¡AY¦U¦¬5Ó¸ÕÅçªÌ¡A«h¦@¬°90¤H¡A 2bÁ{§É¸ÕÅç¹ï¶H¦@295¤H¡A¦©°£90¤H¡A¾l205¤H¡A¦ý¤£·|³o»ò·¥¡AÀ³¸Ó¾l250¤H¥ª¥k¡A ¥t±q³o18Ó¦¬®×¤¤¤ß90¤H¤¤¬D45¤H¸ûÀuªº¼Æ¾Ú¥X¨Ó¡C 250+45=295¤H ¤£ºÞ¬O205¤H©Î250¤H·í´Á¤¤³ø§i³£¤w¨¬°÷ ¦A¾a45¤H©Ô¼Æ¾Ú¡A¬O§_¬ü¤Æ¼Æ¾Ú¡H(³Q¨Ö¦n»ù¿ú)
¥tì®Éµ{¬O§_¦³²§°Ê¡H 1.¦ô2¤ë15¤é´£¥X4»õ¬ü¤¸¶Ò¸êp¹º 2.¦ô3¤ë15¤é«e¤½¥q¤º³¡¸Ñª¼¡B¨Ã§¹¦¨¤@µ§¨p¶Ò»ù¦ô 7¬ü¤¸x80%x88%=4.928¬ü¤¸/ªÑ 3.¦ô4¤ëªì¤½¥¬ASLAN0042b¸Ñª¼µ²ªG(®Éµ{¬O§_²§°Ê¡H)(©Î§ï¬°´Á¤¤³ø§i¡H) ¥]¾P»ù7¬ü¤¸x80%=5.6¬ü¤¸ 4.ASLAN004¼Ú¬w°Ï°Ó·~¤Æ±ÂÅv. (®Éµ{¬O§_§ï¦Ü7¤ë¡H)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/1 ¤W¤È 09:06:17
²Ä 5905 ½g¦^À³
|
¤À§åÁ{§É¸ÕÅ祻¬O©Ò¦³ªºÁ{§É³]p¡D
¥i³v§å¤ñ¹ï¡B§ó±µªñÀH¾÷¸ÕÅç¡D
ºC3Ӥ맹¦¨¡BÁÙ¦b¦X²z½d³ò¡D
Ó¤HÆ[¹îCNTBªº2ÓADÁ{§É¡B ¥i¯à¦p004 1b¡B¦¬¤F¤@©w¤ñ²vªº «D¶Ç²ÎAD±wªÌ¡D
¥L̪º2b°ò½uEASI°¾»´¯g¬Æ¦h¡D
±M·~ªº¦n¦n°µ¥XÀ³¦³ªºÀø®Ä¡B³Ì«n¡D
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/2/1 ¤W¤È 08:53:31
²Ä 5904 ½g¦^À³
|
2¤ë¡A3¤ë¶}©l·s¤@½üÁ{§É¬OÁ׶}12¤ë¤¤¨l¡ã¤¸¤ë¤¤¦¯ªº¡A¼Ú¡B¬ü´H°²¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2023/2/1 ¤W¤È 08:22:22
²Ä 5903 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2023/2/1 ¤W¤È 08:15:32
²Ä 5902 ½g¦^À³
|
COVID-19¬Ì±¡ªº¼vÅT¤w¤T¦~¦h¤F¡A³o®É¤~»¡COVID·|¼vÅT¡Aªí¥Üt³dÁ{§É¾nÀ]¤ÎCEO¥¢Â¾¡A³¯¤j»¡ªº¨S¿ù¡Aªü«iªº½T¤£¾A¥ô¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2023/1/31 ¤U¤È 07:21:38
²Ä 5901 ½g¦^À³
|
2023¦~1¤ë31¤é¡AASLAN Pharmaceuticals Limited¡]¤½¥q¡^¥l开¤F¤@¦¸¯S别ªÑ东¤j会¡]会议¡^¡C¦b这¦¸会议¤W¡A¤½¥qªºªÑ东对两项ú¨议进¦æ¤F§ë²¼¡A这¨Çú¨议¦b¯S别ªÑ东¤j会³qª¾¡]§@为¤½¥q2022¦~12¤ë21¤é´£¥æ给证¨é¥æ©ö©e员会ªº6-Kªí®æªº¥~国¨p¤H发¦æ¤H报§iªºªþ¥ó99.1¡^¤¤¦³©Ò´yz¡A¨C项ú¨议³£±o¨ì¤F开°Ò¸s岛¤½¥qªk¡]×订ª©¡^©M¤½¥q经×订©M«zªº¤½¥q组织³¹µ{¤j纲©M条´Ú规©wªº¥²nªÑ东ªº¥¿¦¡§åã¡C ²Ä1项ú¨议¡C ²Ä 1 号ú¨议¡G§@为¤@项´¶³qú¨议¡Aú¨©w¼W¥[¥»¤½¥qªºªk©wªÑ¥»¡C (A) 从¡C(A) 从5,000,000¬ü¤¸¤À为500,000,000ªÑ´¶³qªÑ¡A¨CªÑ±È为0.01¬ü¤¸¡C (B) ¦Ü¡C10,000,000¬ü¤¸¡A¤À为1,000,000,000ªÑ´¶³qªÑ¡A¨CªÑ±È©Î²¼±É²È为0.01¬ü¤¸¡C 赞¦¨ ¤Ï对 弃权 337,974,366 2,625,200 1,381,425 ²Ä2项ú¨议¡C ²Ä2项ú¨议¡G³q过¤@项¯S别ú¨议¡A¥H·sªº组织³¹µ{¤j纲©M细则¡]§Y¥»¤½¥q²Ä¤Q¤@¥÷经×订©M«zªº组织³¹µ{¤j纲©M细则¡^¥þ±¨ú¥N¥»¤½¥q现¦³ªº组织³¹µ{¤j纲©M细则¡]§Y¥»¤½¥q²Ä¤Q¤@¥÷经×订©M«zªº组织³¹µ{¤j纲©M细则¡^¡C 赞¦¨ ¤Ï对 弃权 338,230,036 2,292,410 1,458,545
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/1/31 ¤U¤È 04:38:04
²Ä 5900 ½g¦^À³
|
³Ìªñªº°ÝÃD¬O¤µ¦~3¤ë©³«e¡AªÑ»ù¦p¥¼¯à¯¸¤W1¬üª÷«ùÄò10¤Ñ¥H¤W¡A
ªÑ²¼´Nn´î¸ê©Î¤U¥«¥i¯à¡A
004 2bÁ{§É¸ÕÅçªø¹F5Ó¦h¤ë¥¼§ó·s¡A¥i¨£¤½¥q¤§µL¯à¤ÎµL¬°¡A¨ä¤¤¨ÃµL¥ô¦ó»¡©ú¡A
¦³»~¾É§ë¸êªÌ¸ÕÅç¤w¹F¦¬®×¤H¼Æ¤§¶ûºÃ¡A£½
¬Ý¼Ë¤l±¡ªp¤w¤£®e¼ÖÆ[¥H¹ï¡A
³o®a¤½¥q«e¬ìõìõìÁj¦ËÃø®Ñ¡A¸Ñª¼«e¼ÖÆ[¡A¸Ñª¼«á¥²±Ñ¡AµL¤@¦¨¥\¡A
¸ÕÅ穵´Á´N§ä²z¥Ñ·e¶ë¡AÂk©SCOVID-19
¸Ñ¨M¤§¹D´N¬O´«±¼µL¯àCEO CARL FIRTH §Ú¤wEMAIL¥h·s¥[©Y¡Aªí¹F°ÝÔ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/31 ¤U¤È 02:42:37
²Ä 5899 ½g¦^À³
|
clinicaltrials.gov/ct2/show/study/NCT01859988?term=NCT01859988&draw=2&rank=1 Dupilumab 2b Á{§É¡A©Û¶Ò¤¤¤ß¦@84Ó¡A¦@13Ӥ맹¦¨16¶gªvÀøªºÀøµ{¼Æ¾Ú¨ú±o¡C ¡]380¤H¡þ6Ó¤£¦PArm)
ASLAN004 2b ,83Ó©Û¶Ò¤¤¤ß¡A295¤H¡þ5 Arm ,¹wp16Ӥ맹¦¨¥Dnªº16¶gªvÀø«áªº¼Æ¾Ú¡C
¦]¨ü¬Ì±¡¼vÅT¡A¸¨«á3Ó¤ë¡Aªñ¤T¦~¨ÓªºÁ{§É´¶¹M¦³ªºª¬ªp¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/31 ¤U¤È 12:40:44
²Ä 5898 ½g¦^À³
|
±Æ°£±ø¥ó¦h¤@±ø. 14.Active COVID infection at baseline. ±Æ°£ °ò½u®Éªº¬¡°Ê©Ê COVID ·P¬V¡C clinicaltrials.gov/ct2/show/NCT05158023
¥»¦¸¼W¥[¤Wz¤@±ø©Û¶Ò®Éªº±Æ°£±ø¥ó. ±Æ°£°ò½uCOVID ·P¬VªÌ¡C
¤]³\¨üCOVID¼vÅT¤Ó¦h,¬°¸É¨¬295¤H¦Ó¦b¤@¶}©l´N¦p¦¹Á{§É³]p?!
¥h¦~¤¸¤ë¤½§G2b Á{§É¥»n¦³100Ó¦¬®×¤¤¤ß,¥B§t¼Ú¬w.
Dupilumab/Lebrikizumab 2b¬Ò¥Î13Ӥ맹¦¨,¦ÓASLAN004 2¤ë¥Î¤F16Ӥ맹¦¨ªì¨B¸ê®Æ¦¬¶°.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/1/31 ¤W¤È 11:59:55
²Ä 5897 ½g¦^À³
|
¦b¬Û¹j5Ó¤ë«á¡A¤~¦b112¦~1¤ë27¤é¤½¥¬¥[¶}¼Ú¬w¦¬®×¤¤¤ß¡A
§Ú»{¬°±¡ªp¤£¦n¡A©Ò¥H¬Q±ß«®À8.7%¡A³o¥Nªí004 2b ¹êÅç¼Æ¾Ú¤í¨Î¡A
¤~»Ýn¦b¬Û¹j20©P«á°µªº¸É±Ï±¹¬I¡A¤£n¦b¦Û§Ú³Â¾K嘞¡An¦U¦Û°k©R嘞¡A
³o®a¤½¥q±q¨Ó¥u³ø³ß¤£³ø¼~
©{¦p¶BÄFªÅ´ß¤½¥q¡Ä |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/31 ¤W¤È 11:56:25
²Ä 5896 ½g¦^À³
|
¤µ¦~6¤ë©³§¹¦¨16¶gªvÀøªºªì¨BÁ{§É¸ê®Æ¦¬¶°¡C ¤¸¤ë©³¶}©l©Û¶Ò¡A3¤ëªì§¹¦¨³Ì«á¤@§å18Ó¤¤¤ßªº²Ä¤@¾¯ª`®g¡C¡]2¤ë©³¡ã3¤ëªì¤½¥¬§¹¦¨©Û¶Ò¡^
18¡þ83=20%
¤½¥q¤w¦³80%ªº16¶gªvÀø§¹¦¨ªº¥¼¸Ñª¼¸ê®Æ¡C
¥[¤J¼Ú¬wÁ{§É¡]¥HªiÄõ°µ¥Nªí¡^¡A¥»¦¸18Ó¤¤¤ß¬Ò¬°ASLNªºÁ{§É¤¤¤ß¡AªÖ©wÄY®æ¿zÀË©Û¶Ò¤H¿ï¡A¨CÓ¤¤¤ß¥§¡©Û3¡ã4¦ì±wªÌ¡A §Æ±æ¥i±NªvÀø«áªº¦U¶µ«ü¼Ð¦A¥Î¦¹20%©Ô¤É¡A¾ãÓÁ{§É³]p¬Û·í¤p¤ß¡A±M·~¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/31 ¤W¤È 11:11:49
²Ä 5895 ½g¦^À³
|
clinicaltrials.gov/ct2/show/NCT05158023 Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis
³Ì·sÁ{§É§ó·s: 2023/01/30 1.¦¬®×¤¤¤ß¥Ñ65Ó¼W¥[¦Ü83Ó,¼W¥[¼Ú¬wªiÄõ9Ó...
2.Estimated Primary Completion Date : June 30, 2023(¥i¯àªº¸Ñª¼¤é´Á?)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/26 ¤U¤È 06:17:37
²Ä 5894 ½g¦^À³
|
¤ÀªR®v¥Ø¼Ð»ù7¬ü¤¸
2b ITT¸Ñª¼µ²ªG²Å¦X 1.IGA0,1=44%vs15%(¹ï·Ó组)¡B ¥H¤W¦p1bªºmITT¡D
Ó¤H¦ôIGAÀ³¦b50%~60%¤§¶¡¾÷²v¤j¡D
¬G²Ä¤@µ§ªº¨p¶Ò»ù¥i¯à¶W¥X¤W¤@½g¤åªº预´Á«Ü°ª¡B¦³¾÷·|¿¼Æ¡D 14x80%x88%....¤£µL¥i¯à?!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/26 ¤U¤È 05:29:14
²Ä 5893 ½g¦^À³
|
®Éµ{¡G 1.¤¸¤ë31¤éªÑªF·|¡B´£°ªªÑ¥»¦Ü20¸U¤dªÑADR¡B¥Ø«e¤wµo¦æ7¸U¤dªÑ¡B¥t¥~¤@¸U¤dªÑ¬°¤½¥q¤º³¡¤Hû¿EÀyp¹º¡D 2.¦ô2¤ë15¤é´£¥X4»õ¬ü¤¸¶Ò¸êp¹º 3.¦ô3¤ë15¤é«e¤½¥q¤º³¡¸Ñª¼¡B¨Ã§¹¦¨¤@µ§¨p¶Ò»ù¦ô 7¬ü¤¸x80%x88%=4.928¬ü¤¸/ªÑ 4.¦ô4¤ëªì¤½¥¬ASLAN0042b¸Ñª¼µ²ªG ¥]¾P»ù7¬ü¤¸x80%=5.6¬ü¤¸ x7¸U¤dªÑ. 5¡DASLAN004¼Ú¬w°Ï°Ó·~¤Æ±ÂÅv. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/24 ¤W¤È 07:27:17
²Ä 5892 ½g¦^À³
|
ASLAN004 ªvÀø¦³¨Ï¥Î¹LDupilumab¡]¤G½u¥Íª«»s¾¯¡^Á{§É¹êÅç¤w¸g©ó¤W¤ë21¤é¶}©l¡C ¥Ø«e¶}³]¬ü°ê¤@Ó¤¤¤ß©Û¶Ò¤¤¡C
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
clinicaltrials.gov/ct2/show/NCT05694884?term=Study+of+Eblasakimab+in+Male&draw=2&rank=1
Study Design Go to sections Study Type : Interventional (Clinical Trial) Estimated Enrollment : 75 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab Actual Study Start Date : December 21, 2022 Estimated Primary Completion Date : December 16, 2023 Estimated Study Completion Date : December 16, 2023 |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2023/1/22 ¤U¤È 08:34:31
²Ä 5891 ½g¦^À³
|
¤µ¦~´N¬O¤µ¦~¤F «ù¦³¨È·à±d³o»ò¤[¡A¤µ¦~¬OÃöÁä¤@¦~ ¯¬¨È·à±d¤µ¦~¼Æ¾Ú¦n¨ìÃzªí ¯¬·à¤Í¨ß¦~¸U¨ß¶¶§Q¡A°]·½¼s¶i |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³v®ö«È10146323 |
µoªí®É¶¡:2023/1/22 ¤U¤È 06:15:54
²Ä 5890 ½g¦^À³
|
Ä@ ¨¦üµÐ´£µL¾ð¡A¤ß¦p©úÃèµL¥x¡A ©Ù«o¹Ð®JµLµ·¡AÀ³µL©Ò¦íµLê¡I
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/22 ¤W¤È 07:51:34
²Ä 5889 ½g¦^À³
|
·sÄ@µÐ´£¦¨ ¦~¦~¬Ò¥¦w §Ö®©Æ[¦Û¦b ¼ÖÐä¨ì©¼©¤ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥d¦b¥b¤s¸y10153098 |
µoªí®É¶¡:2023/1/22 ¤W¤È 12:06:50
²Ä 5888 ½g¦^À³
|
½Ð°Ý¦U¦ì¤j¤j ¸Ñ¦£¦¨¥\·§²v°ª¶Ü ¥H«e¦b¥xªÑ¶Rªº §Ñ¤FÂàadr ¤@ª½«ù¦³¨ì²{¦b ·Ç³Æ¦bÉu¥L¤@¦¸ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯¤p©ú10152293 |
µoªí®É¶¡:2023/1/20 ¤U¤È 12:08:30
²Ä 5887 ½g¦^À³
|
·sªº¤@¦~¡A·sªº§Æ±æ
³o»ò¦h¦~¤F¡A·PÁ¤j®a¤@ª½ªº¤À¨É¡A
¯¬¤j®a·sªº¤@¦~¹Ú·Q¦¨¯u¡A
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2023/1/18 ¤U¤È 12:41:58
²Ä 5886 ½g¦^À³
|
½Ð°Ý TREK-DX ¤½¥q¦³¤½§i¦¬®×¤¤¤ß¦¨¥ß¶¡¼Æ¤F¶Ü?? ÁÂÁÂ
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2023/1/17 ¤W¤È 11:43:28
²Ä 5885 ½g¦^À³
|
¦p¤Ñ©R¤jª÷¤f¡A§Æ±æ´Á¤¤¼Æ¾Ú«ü¤Þ¥¿¦V¸Ñª¼µ²ªG¡AÅý¤@¤Á¨«¦V¨ÖÁÊ«eªº°ªªÑ»ù~¥[ªo¡A·à¤ÍÌ·s¬K´r§Ö! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2023/1/14 ¤U¤È 03:42:44
²Ä 5884 ½g¦^À³
|
Y2b IGA0,1>53%¥H¤W®É
¥]¾P³æ»ù©Ô°ª¨é°Ó¥Ø¼Ð5.6¬ü¤¸¤@ªÑªº4¿=5.6*4=22.4¬ü¤¸¡C
«h¥»¦¸©Ò»Ý7¸U¤dªÑADR¥i°¬°1/4=1¡P75¸UªÑ´N°÷¶Ò¨ì3¡P8»õ¬ü¤¸¸êª÷
«h¦~©³³Q¨ÖÁʪѥ»¡×7+1+1¡P75¡×9¡P75¸UªÑADR
50»õ¬ü¤¸¦¬Áʪ÷ÃB¡þ9¡P75¸U¤dªÑ¡×50¬ü¤¸¡þªÑ¤@¤@ADR
¥H¤W¼ÒÀÀ¡A
Ų½ÐASLN ¤½¥q¤Å¥²±N2b¥]¾P¡þ¨p¶Ò»ù®æ©Ô°ª¨ì¦X²z»ù®æ¡C |
|
¡@ |
¦^°Q½×°Ï1¶ |
<< 701 ~ 800 «h¦^ÂÐ >> |